Toxicology

A special contribution from the American Association of Poison Control Centers.



1986 Annual Report of the American Association of Poison Control Centers National Data Collection System

TOBY L. LITOVITZ, MD, THOMAS G. MARTIN, MD, BARBARA SCHMITZ, RN

The American Association of Poison Control Centers (AAPCC) National Data Collection System has grown since its inception in 1983. During that pilot year, 251,012 human poison exposures were reported from 16 poison centers. In 1984 and 1985, 730,224 and 900,513 human exposures were reported, respectively. This report includes 1,098,894 human exposure cases reported by 57 participating poison centers during 1986.

CHARACTERIZATION OF PARTICIPATING CENTERS

All 57 reporting centers submitted data for the entire year. Twenty-six of the 57 centers were certified as regional poison control centers by the AAPCC. Annual center call volumes (human exposure cases only) ranged from 1,273 to 72,351 (mean, 19,525). Center penetrance (defined as the number of human poison exposure cases reported to a center divided by the

From the Data Collection Committee, American Association of Poison Control Centers.

The authors acknowledge the generous contribution of Micromedex, Inc., to the programming and processing of this annual report.

Centers participating in this year's report include Alabama Poison Center, Tuscaloosa, AL; Arizona Poison Control System, Tucson, AZ; St. Luke's Poison Center, Phoenix, AZ; Fresno Community Hospital Regional Poison Control Center, Fresno, CA; Orange County Poison Center, Orange, CA; San Diego Regional Poison Center, San Diego, CA; San Francisco Bay Area Regional Poison Center, San Francisco, CA; Rocky Mountain Poison Center, Denver, CO; National Capital Poison Center, Washington, DC; Tampa Bay Regional Poison Center, Tampa FL; Idaho Poison Control Center, Boise, ID; Indiana Poison Center, Indianapolis, IN; St. Luke's Poison Center, Sioux City, IA: Mid-America Poison Center, Kansas City, KS; Kentucky Regional Poison Center of Kosair-Children's Hospital, Louisville, KY; Louisiana Regional Poison Control Center, Shreveport, LA; Maryland Poison Center, Baltimore, MD; Children's Hospital of Michigan Poison Control Center, Detroit MI; Blodgett Regional Poison Center, Grand Rapids, MI; Great Lakes Poison Control Center, Kalamazoo, MI; Midwest Poison Center, Kalamazoo, MI; Saginaw Regional Poison Center, Saginaw, MI; Hennepin Poison Center, Minneapolis, MN; Minnesota Poison Control System, St. Paul, MN; St. Louis Regional Poison Center, St. Louis, MO; Mid-Plains Poison Control Center, Omaha, NE; New Jersey Poison Information and Education System, Newark, NJ; Hudson Valley Poison Center, Nyack, NY; Triad Poison Center,

Greensboro, NC; North Dakota Poison Center, Fargo, ND; Akron Regional Poison Center, Akron, OH; Stark County Poison Control Center, Canton, OH: Greater Cleveland Poison Control Center, Cleveland, OH; Central Ohio Poison Control Center, Columbus, OH; Oregon Poison Center, Portland, OR; LeHigh Valley Poison Center, Allentown, PA; Keystone Regional Poison Center, Altoona, PA; Northwest Poison Center, Erie, PA; Capital Area Poison Center, Hershey, PA; Delaware Valley Regional Poison Control Center, Philadelphia, PA; Pittsburgh Poison Center, Pittsburgh, PA; Rhode Island Poison Center, Providence, RI; Southern Poison Center, Inc., Memphis, TN; North Central Texas Poison Center, Dallas, TX; Intermountain Regional Poison Control Center, Salt Lake City, UT; Blue Ridge Poison Center, Charlottesville, VA; Tidewater Poison Center, Norfolk, VA; Central Virginia Poison Center, Richmond, VA; Seattle Poison Center, Seattle, WA; Spokane Poison Center, Spokane, WA; Mary Bridge Poison Center, Tacoma, WA; Central Washington Poison Center, Yakima, WA; West Virginia Poison Center, Charleston, WV; Eau Claire Poison Center, Eau Claire, WI; LaCrosse Area Poison Center, LaCrosse, WI; University of Wisconsin Hospital Regional Poison Control Center, Madison, WI; Milwaukee Children's Hospital Poison Center, Milwaukee, WI.

© 1985, 1986, 1987, by the American Association of Poison Control Centers. Published by permission. All rights reserved.

Address reprint requests to Dr. Litovitz: National Capital Poison Center, Georgetown University Hospital, 3800 Reservoir Road, NW, Washington, DC 20007.

 $0735-6757/87 \ \$0.00 + .25$




FIGURE 1. Fifty-seven centers participated in the Data Collection System in 1986. The cross-hatched areas denote regions served by reporting centers. (Map adapted from Hammond's Outline Map of the United States.)

TABLE 1. Site of Caller and Site of Exposure, Human Exposure Cases

	Site of Caller (%)	Site of Exposure (%)
Residence	82.1	91.6
Health care facility	14.1	0.5
Workplace	1.5	2.5
School	0.6	8.0
Other	1.3	2.1
Unknown	0.5	2.4
TOTAL	100.0	100.0

population served by that center) ranged from 3.1 to 19.9/1,000, with a mean of 9.1 reported exposures per thousand population.

A total population of 132.1 million was served by the participating centers including portions of 33 states and the District of Columbia (Fig. 1). Noting the 241.1 million estimated United States population, the data presented represent an estimated 55% of the human poison exposures reported to poison control centers in the United States during 1986. Thus, the 1,098,894 human poison exposures reported in this data base can be extrapolated to predict a nationwide

TABLE 2. Age and Sex Distribution of Human Poison Exposure Cases*

Age (yr)	Male	Female	Unknown	Total
<1	46,538 (4.2)	41,834 (3.8)	1,246 (0.1)	89,618 (8.2)
1	111,421 (10.1)	97,475 (8.9)	2,112 (0.2)	211,008 (19.2)
2	115,748 (10.5)	97,827 (8.9)	2,275 (2.1)	215,850 (19.6)
3	55,890 (5.1)	46.194 (4.2)	1,183 (0.1)	103,267 (9.4)
4	24.629 (2.2)	19,389 (1.8)	514 (0.0)	44,532 (4.1)
5	13.031 (1.2)	10.236 (0.9)	315 (0.0)	23,582 (2.1)
6-12	32.699 (3.0)	24,044 (2.2)	792 (0.1)	57,535 (5.2)
3-17	19.330 (1.8)	27,498 (2.5)	507 (0.0)	47,335 (4.3)
>17	122,646 (11.2)	157,593 (14.3)	4,112 (0.4)	284,351 (25.9)
Jnknown†	7,582 (0.7)	8,678 (0.8)	5,556 (0.5)	21,816 (2.0
TOTAL	549,514 (50.0)	530,768 (48.3)	18,612 (1.7)	1,098,894 (100.0

^{*} Numbers in parentheses are percentages.

[†] In the unknown category, although the exact age was not reported, 915 cases were infants and 3,810 were children aged 2 to 5 years.

TABLE 3. Distribution of Age and Sex of 406 Fatalities

Age (yr)	Male	Female	Unknown	Total*
<1	3	1	1	5 (1.2
1	3	2	0	5 (1.2
2	2	1	0	3 (0.7
3	1	0	0	1 (0.2
4	1	0	0	1 (0.2
5	0	0	0	0 (0.0
6-12	2	0	0	2 (0.5
13-19	22 ·	19	0	41 (10.1
20-29	55	. 35	0	90 (22.2
30-39	46	25	0	71 (17.5
40-49	19	25	0	44 (10.8
50-59	26	23	0	49 (12.1
60-69	11	27	0	38 (9.4
70-79	13	14	0	27 (6.7
80-89	4 ,	5	0	9 (2.2
90-99	0	3	0	3 (0.7
Unknown adult	10	6	0	16 (3.9
Unknown	0	0	1	1 (0.2
TOTAL	218	186	2	406 (100.0

^{*} Data in parentheses are percentages.

TABLE 4. Number of Substances Involved in Human Poison Exposure Cases

Number of	Cases			
Substances	No.	%		
1	1,027,452	93.5		
2	53,759	4.9		
3	9,949	0.9		
4	2,726	0.2		
5	1,011	0.1		
6	433	0.0		
7	179	0.0		
8	92	0.0		
9	65	0.0		
≥10	231	0.0		
Unknown	2,997	0.3		
TOTAL	1,098,894	100.0		

incidence of 2 million human poison exposures. However, extrapolations from the number of reported poisonings to the number of actual poisonings occurring annually in the United States cannot be made from these data alone, as considerable variations in poison center penetrance were noted. Indeed, assuming all centers reached the penetrance level of 19.9 poisonings/1,000 population reported for one state, then 4.8 million poisonings would have been reported to poison control centers in 1986. Because of the growth and development of this relatively new data collection project, with increasing center participation from year to year, the data do not directly identify a trend in the overall incidence of poisonings in the United States. However, an analysis of data from 47 centers that par-

TABLE 5. Reason for Human Poison Exposure Cases

	No.	%
Accidental		
General	930,320	84.7
Misuse*	24,345	2.2
Occupational	19,115	1.7
Environmental	5,237	0.5
Unknown	1,192	0.1
TOTAL	980,209	89.2
Intentional		
Suicidal	61,788	5.6
Abuset	12,841	1.2
Misuse‡	11,312	1.0
Unknown	10,190	0.9
TOTAL	96,131	8.7
Adverse Reaction		
Drug	7,751	0.7
Food	6,079	0.6
Other	1,424	0.1
TOTAL	15,254	1.4
Unknown	7,300	0.7
TOTAL	1,098,894	100.0

^{*} Improper use of a substance where therapeutic or beneficial results were intended, e.g., an overdose occurring because both parents gave the same medication to a child and neither was aware (at the time) of the other's action, or a case where misreading the label of a product results in an unintended exposure.

[†] Improper use of a substance where the patient was seeking a psychotropic effect.

[‡] Intentional incorrect use of a substance where a psychotropic effect was not sought, e.g., intentional excessive dosing to obtain a more rapid or superior pharmacologic effect for presumed "therapeutic purposes."

TABLE 6. Distribution of Reason for Exposure by Age, Human Exposure Cases Only*

Reason	<6 Years	6-12 Years	13-17 Years	>17 Years	Unknown	Total
Accidental	687,801 (99.3)	53,334 (92.7)	23,962 (50.6)	202,180 (71.1)	12,932 (75.7)	980,209 (89.2)
Intentional	1,105 (0.2)	2,712 (4.7)	21,943 (46.4)	66,857 (23.5)	3,514 (20.1)	96,131 (8.7)
Adverse reaction	1,774 (0.3)	1,037 (1.8)	693 (1.5)	11,380 (4.0)	370 (2.2)	15,254 (1.4)
Unknown	1,902 (0.3)	452 (0.8)	737 (1.6)	3,935 (1.4)	274 (1.6)	7,300 (0.7)
TOTAL	692,582 (63.0)	57,535 (5.2)	47,335 (4.3)	284,352 (25.9)	17,090 (1.6)	1,098,894 (100.0)

^{*} Data in parentheses are percentages.

 TABLE 7. Distribution of Reason for Exposure and Age for 406 Human Fatalities

	<6 Years	6-12 Years	13-17 Years	>17 Years	Unknown	Total
Accidental						
General	9	1	0	10	0	20
Environmental	1	1	2	8	0	12
Misuse	3	0	2	13	0	18
Occupational	0	0	0	5	0	5
Unknown	. 0	0	0	4	0	4
TOTAL	13	2	4	40	0	59
Intentional						
Suicide	0	0	16	207	0	223
Misuse	0	0	1	12	0	13
Abuse	1	0	3	40	1	45
Unknown	0	0	1	31	0	32
TOTAL	1	0	21	290	1	313
Adverse Reaction	0	0	0	4	0	4
Unknown	1	0	0	29	0	30
TOTAL	15	2	25	363	1	406

TABLE 8. Distribution of Route of Exposure for Human Poison Exposure Cases and 406 Fatalities*

	All Cases	Fatalities
Ingestion	897,518 (78.5)	326 (77.1)
Dermal	75,127 (6.6)	4 (0.9)
Ophthalmic	63,558 (5.6)	0 (0.0)
Inhalation	60,520 (5.3)	46 (10.9)
Bites and stings	35,395 (3.1)	1 (0.2)
Parenteral	3,524 (0.3)	31 (7.3)
Other/unknown	7,496 (0.7)	15 (3.5)

^{*} Multiple routes of exposure were observed in many poison exposure victims. Percentages (in parentheses) are based on the total number of exposure routes (1,143,138 for all patients, 423 for fatal cases) rather than the total number of human exposures (1,098,894) or fatalities (406).

TABLE 9. Symptom Assessment at Time of Initial Call to Poison Center

Symptomatic, related to exposure Symptomatic, unrelated to exposure Symptomatic, unknown if related	No. (%)	
Asymptomatic	725,129	(66.0)	
Symptomatic, related to exposure	285,811	(26.0)	
Symptomatic, unrelated to exposure	17,273	(1.6)	
Symptomatic, unknown if related	48,230	(4.4)	
Unknown	22,451	(2.0)	
TOTAL	1,098,894	(100.0)	

TABLE 10. Management Site of Human Poison Exposure Cases

No. (%)	
820,629	(74.7)	
127,807	(11.6)	
125,694	(11.4)	
24,764	(2.3)	
1,098,894	(100.0)	
	127,807 125,694 24,764	

ticipated for the entirety of 1985 and 1986 indicates an 8.4% increase in reported poison exposures from 1985 to 1986 within the regions served by these 47 centers.

REVIEW OF THE DATA

The 1,098,894 human poison exposures reported to AAPCC in 1986 represent the largest poison exposure data base ever compiled in the United States and an 18.1% increase in total reports from 1985. An analysis of the data indicates that 91.6% of exposures occurred in the home (Table 1). Two unlikely sites of poisonings, health care facilities and schools, accounted for 5,716 (0.5%) and 9,147 (0.8%) poison exposures, respectively. Poison center peak call volumes were

noted from 5 to 9 PM, although call frequency remained consistently high between 9 AM and 10 PM, with 82.6% of calls logged during this 13-hour period.

The age and sex distribution of human poison exposure victims is outlined in Table 2. Forty-seven percent of cases involved children under 3 years of age, and 62.6% occurred in children under 6 years of age. A male predominance is found among poison exposure victims less than 12 years old, but the gender distribution is reversed in teenagers and adults. Table 3 gives the age and sex distribution for 406 fatalities. Despite variations from decade to decade among adults, overall, males account for a greater number of fatalities in children, teenagers, and adults.

A single substance was implicated in 93.5% of reports, and only 1.3% of patients were exposed to more than two possibly poisonous drugs or products (Table 4). Most cases of human exposure were acute (98.7%), as were most poison-related fatalities (91.1%). (Chronic exposures were arbitrarily defined as repeated exposures to the same toxic substance or a single exposure lasting longer than eight hours.)

Most poison exposures (89.2%) were accidental; suicidal intent was present in 5.6% of cases (Table 5). Nearly one quarter (23.2%) of cases with suicidal intent occurred in patients who were 13 to 17 years old. Whereas accidental poisonings outnumbered both intentional poisonings and adverse reactions in all age groups (Table 6), the ratio was lower in teenage and adult cases. In contrast, of the 406 human poisoning fatalities reported, this ratio was reversed among the adult deaths, with 7.25 times as many deaths resulting from intentional as compared with accidental exposures (Table 7).

Ingestions accounted for 78.5% of poison exposures (Table 8), followed in frequency by dermal contact, ophthalmic exposure, inhalation, bites and stings, and parenteral exposure. For the 406 fatalities, ingestion and inhalation were the predominant exposure routes.

Table 9 displays the symptom assessment at the time of the initial call to the participating poison center. In addition to the 26.0% of patients with initial symptoms clearly related to the exposure, symptoms developed during the subsequent course in 8,413 initially asymptomatic patients. Thus, symptoms definitely related to the exposure eventually developed in at least 26.8% of patients.

Most of the patients reported to poison centers were managed in a non-health care facility (74.7%), usually at the site of exposure, the patient's own home (Table 10). Treatment in a health care facility was rendered or recommended in 23.0% of cases, and of these, 53.0% involved treatment and release, 17.3% involved admission for medical care, and 2.3% involved admission for psychiatric treatment; 8.5% refused referral, and 19.0% were lost to follow-up.

INDICE 11. IMEGICAL CUICOME OF HUMBAN POISON EXPOSURE CASES BY PAHENT AGE	ison Exposure cases by Fa	afe mem					
	<6 Years	6-12 Years	13-17 Years	>17 Years	Unknown	Total	
No effect	404,125 (58.4)	21,974 (38.2)	11,937 (25.2)	52,736 (18.5)		494,707	(45.0)
Minor effect	90,917 (13.1)	17,337 (30.1)	18,670 (39.4)	118,737 (41.8)	5,325 (31.2)	250,986	(22.8)
Moderate effect	4,616 (0.7)	1,275 (2.2)	3,196 (6.8)	20,271 (7.1)		29,937	(2.7)
Major effect	627 (0.1)	95 (0.2)	321 (0.7)	2,981 (1.0)		4,101	(0.4)
Death	15 (0.0)	2 (0.0)	25 (0.1)	363 (0.1)		406	(0.0)
Unknown, nontoxict	159,997 (23.1)	11,946 (20.8)	5,376 (11.4)	35,819 (12.6)		215,590	(19.6)
Unknown, potentially toxict	20,425 (2.9)	3,196 (5.6)	6,648 (14.0)	40,752 (14.3)		74,960	(8.9)
Unrelated effect	9,446 (1.4)	1,523 (2.6)	1,001 (2.1)	11,630 (4.1)		24,122	(2.2)
Unknown	2,414 (0.3)	187 (0.3)	161 (0.3)	1,063 (0.4)	260 (1.5)	4,085	(0.4)
TOTAL	692,582 (63.0)	57,535 (5.2)	47,335 (4.3)	284,352 (25.9)	17,090 (1.6)	1,098,894 ((100.0)
* Data in properties are are represented as							

No follow-up provided as exposure was assessed as nontoxic. Patient lost to follow-up. Exposure was assessed as potentially toxic. Data in parentheses are percentages.

TABLE 12. Distribution of Medical Outcome by Reason for Exposure for Human Poison Exposure Victims*

	Accidental	Intentional	Adverse Reaction	Unknown	Tota	Total	
No effect	474,546 (43.2)	17,082 (1.6)	1,607 (0.1)	1,472 (0.1)	494,707	(45.0)	
Minor effect	208,248 (19.0)	33,261 (3.0)	7,726 (0.7)	1,751 (0.2)	250,986	(22.8)	
Moderate effect	18,288 (1.7)	10,112 (0.9)	1,044 (0.1)	493 (0.0)	29,937	(2.7)	
Major effect	1,621 (0.1)	2,299 (0.2)	75 (0.0)	106 (0.0)	4,101	(0.4)	
Death	59 (0.0)	313 (0.0)	4 (0.0)	30 (0.0)	406	(0.0)	
Unknown, nontoxic	206,647 (18.8)	5,754 (0.5)	1,820 (0.2)	1,369 (0.1)	215,590	(19.6)	
Unknown, potentially toxic	45,921 (4.2)	25,709 (2.3)	1,667 (0.2)	1,663 (0.2)	74,960	(6.8)	
Unrelated effect	21,257 (1.9)	1,241 (0.1)	1,268 (0.1)	356 (0.0)	24,122	(2.2)	
Unknown	3,622 (0.3)	360 (0.0)	43 (0.0)	60 (0.0)	4,085	(0.4)	
TOTAL	980,209 (89.2)	96,131 (8.7)	15,254 (1.4)	7,300 (0.7)	1,098,894	(100.0)	

^{*} Data in parentheses are percentages.

Table 11 shows the medical outcome of the human poison exposure victims distributed by age, emphasizing the more severe outcome observed in the older age groups. Table 12 compares medical outcome and reason for exposure, emphasizing the greater frequency of serious outcome in intentional exposures.

Table 13 outlines the use of initial decontamination

TABLE 13. Therapy Provided in Human Poison Exposure Cases

	No.
Initial decontamination	
Dilution	423,744
Irrigation/washing	201,583
lpecac syrup	145,949
Activated charcoal	56,619
Cathartic	47,013
Gastric lavage	17,639
Other emetic	2,537
Measures to enhance elimination	
Urinary alkalinization (with or without diuresis)	2,347
Forced diuresis	300
Hemodialysis	297
Hemoperfusion (charcoal)	99
Urinary acidification (with or without diuresis)	75
Peritoneal dialysis	62
Exchange transfusion	33
Hemoperfusion (resin)	23
Specific antidote administration	
N-acetylcysteine (PO)	3,009
Naloxone	3,209
Atropine	529
Deferoxamine	506
Ethanol	453
Physostigmine	375
Antivenin/antitoxin	349
Hydroxocobalamin	202
N-acetylcysteine (IV)	153
Pralidoxime (2-Pam)	151
Dimercaprol (BAL)	147
Penicillamine	130
Fab fragments	105
Pyridoxine	103
Methylene blue	90
Cyanide antidote kit	84
EDTA	84

procedures, specific antidotes, and measures to enhance elimination in the treatment of patients reported in this data base. These figures must be interpreted as minimum frequencies because of the limitations of telephone data gathering. Ipecac syrup was administered in 13.3% of cases. In children, ipecac syrup was most often administered outside a health care facility (Table 14).

A summary of the 406 fatal exposures is presented in Table 15. Each of these cases was abstracted and/or verified by the reporting center, with only those fatalities deemed "probably" or "undoubtedly" related to the exposure included in this compendium. Confirmation of the cause of death by a postmortem report was obtained in 38.9% of cases. The highest blood level of implicated substances is provided where available to the reporting poison center. Cases with prehospital cardiorespiratory arrests are indicated. Abstracts are provided in the appendix for interesting or unusual cases.

Tables 16 and 17 provide comprehensive demographic data on patient age, reason for exposure, medical outcome, and use of a health care facility for all 1,098,894 exposures, presented by category. Table 16 focuses on nonpharmaceuticals; Table 17 presents drugs. Table 18 presents the most common categories listed by frequency of exposure. Table 19 lists the substance categories with the largest number of reported deaths.

A review of the fatality data demonstrates that 29.6% of the patients experienced cardiorespiratory arrest prior to arrival in the emergency department. Of the 49 patients who intentionally inhaled or injected toxins, 34 (69.4%) sustained a prehospital cardiac arrest. The 10 patients who ingested cyanide also experienced a higher incidence of prehospital cardiac arrest (70%); of the remaining three cases, two were agonal on presentation. In 19 ethylene glycol or methanol fatalities, diagnosis was substantially delayed in seven (36.8%), and two never received ethanol-blocking therapy.

TABLE 14. Ipecac Administration by Site and Age*

Age (yr)	Non-health Care Facility	Health Care Facility	Unknown	Total
<1	3,841 (2.6)	1,653 (1.1)	4 (0.0)	5,507 (3.8)
1	18,929 (13.0)	7,541 (5.2)	28 (0.0)	26,526 (18.2)
2	25,921 (17.8)	11,941 (8.2)	56 (0.0)	37,951 (26.0)
3	13,653 (9.4)	5,949 (4.1)	36 (0.0)	19,662 (13.5)
4	4,907 (3.4)	2,100 (1.4)	14 (0.0)	7,026 (4.8)
5	1,996 (1.4)	815 (0.6)	3 (0.0)	2,818 (1.9)
6-12	3,006 (2.1)	1,617 (1.1)	7 (0.0)	4,636 (3.2)
13-17	967 (0.7)	8,199 (5.6)	9 (0.0)	9,182 (6.3)
>17	5,208 (3.6)	22,404 (15.4)	31 (0.0)	27,667 (19.0)
Unknown	2,521 (1.7)	2,412 (1.7)	10 (0.0)	4,974 (3.4)
TOTAL	80,949 (55.5)	64,631 (44.3)	198 (0.1)	145,949 (100.0)

^{*} Data in parentheses are percentages.

 TABLE 15.
 Summary of Fatal Exposures

	Age		Route of		
Case	(yr)	Substances	Exposure	Reason	Blood Levels**
Adhesives					
1*	29	Glue: methylene chloride, trichloroethane, diethyl ether	Inhalation	Acc occup	
Alcohols					
2*	51	Ethanol benzodiazepines	Ingestion	Int unknown	511 mg/dl
3†	ໍ 60	Isopropanol	Parenteral	Acc misuse	
4*	17	Methanol	Ingestion	Acc misuse	40 mg/dl, 36 hr
5	19	Methanol	Ingestion	Int unknown	· 170 mg/dl
6	24	Methanol	Ingestion	Int suicide	46 mg/dl
7‡	29 .	Methanol, methylene chloride toluene	Ing and inh	Int suicide	109 mg/dl
8* †	48	Methanol	Ingestion	Int unknown	585 mg/dl
9 `	55	Methanol	Ingestion	Int unknown	J

See also cases 13, 78, 95, 124, 127, 150, 172, 193, 198, 200, 236, 237, 238, 249, 290, 294, 304, 324, 327, 333, 347, 357, 387, 388, 389, 390 (ethanol).

Typewrite	r correction	n fluids (TCF)			
10	15	Trichloroethane	Inhalation	Int abuse	
11*	16	Trichloroethane/ethylene	Inhalation	Int abuse	
12*‡	18	Trichloroethane	Inhalation	Int abuse	
13‡	32	TCF (unknown ingredients) paint	Inhalation	Int abuse	
		ethanol	Ingestion		140 mg/dl
Automotive/	aircraft/hos	- *****	ingestion		140 Mg/di
14	26	Ethylene glycol antifreeze	Ingestion	Int suicide	
15	28	Ethylene glycol antifreeze	Ingestion	Int unknown	
16	37	Ethylene glycol antifreeze	Ingestion	Int suicide	525 mg/dl
17	44	Ethylene glycol antifreeze	Ingestion	Int suicide	584 mg/dl
18	24	Methanol gasoline antifreeze	Ingestion	Int unknown	3
19	27	Methanol	Ingestion	Unknown	200 mg/dl
20	28	Methanol windshield wash	Ingestion	Int suicide	233 mg/dl
21	55	Methanol windshield wash	Ingestion	Int unknown	135 mg/dl, >24 hr
22*	55	Methanol gasoline antifreeze	Ingestion	Int suicide	203 mg/dl
Bites and er	nvenomatio	ns			
23†	69	Brown recluse spider bite	Bite/sting	Acc gen	
Chemicals					
24	25	Cyanide	Ingestion	Int suicide	2.5 mg/L
25*†	26	Cyanide	Ingestion	Int suicide	
26*	27	Cyanide	Ingestion	Int suicide	
27†	28	Cyanide	Ingestion	Int suicide	
28*	37	Cyanide	Inhalation	Int suicide	
29*	40	Cyanide (capsule tampering)	Ingestion	Int misuse	
					411

TABLE 15. Continued

Case	Age (yr)	Substances	Route of Exposure	Reason	Blood Levels**
30*	41	Cyanide	Inhalation	Int suicide	
31*	47	Cyanide	Ingestion	Int suicide	
32*	48	Cyanide	Ingestion	Acc unknown	
33	52	Cyanide (capsule tampering)	Ingestion	Int misuse	
34†	29	Ethylene glycol	Ingestion	Int suicide	154 mg/dl, 18 hi
35†	32	Ethylene glycol	Ingestion	Unknown	
36‡	62	Ethylene glycol	Ingestion	Int unknown	
37	78	Ethylene glycol	Ingestion	Unknown	
38	31	Hydrochloric acid	Ingestion	Int suicide	
39†	22	Hydrofluoric acid	Dermal	Acc occup	700 / 10
40†	33	Hydrofluoric acid	Ingestion	Int suicide	720 μg/ml§
41	19	Methylene chloride	Ing, inh, derm	Unknown	00.00/
42	>17	Methemoglobin producer	Unknown	Int unknown	88.0%
43*†	58 68	Strychnine (nux vomica)	Ingestion	Acc misuse	
44		Sodium hydroxide (lye)	Ingestion	Unknown	
		lene chloride).			
Cleaning su 45	ibstances 45	Alkaline drain opener	Ingestion	Int suicide	
45 46	73	Alkaline drain opener Alkaline drain opener	Ingestion	Int suicide	
46 47	73 74	Ammonia (household)	Ingestion	Int suicide	
48†	67	Brass cleaner (chromic acid,	Ingestion	Int suicide	
401		sodium bisulfate/bifluoride)	mgoston	int datoldo	
49	67	Cationic cleaner	Ingestion	Acc unknown	
50	84	Cationic cleaner	Ingestion	Acc gen	
51	85	Cationic cleaner-industrial	Ingestion	Acc gen	
52	3 mo	Spot remover (naphtha)	Ingestion	Int abuse	
53	39	Toilet bowl cleaner (HCI)	Ingestion	Int suicide	
54	40	Toilet bowl cleaner (HCI)	Ingestion	Acc gen	
55†	43	Toilet bowl cleaner (HCI)	Ingestion	Int suicide	
56	56	Toilet bowl cleaner (HCI)	Ingestion	Int suicide	
57†	59	Toilet bowl cleaner (HCI)	Ingestion	Int suicide	
58	>17	Toilet bowl cleaner (HCI)	Ingestion	Acc gen	
-	personal care				•
		ave, ethanol), 123 (acetone, nail polish re	emover).		
	es, and vapors		la la al aki a m	A	
59*	>17	Anhydrous ammonia	Inhalation	Acc occup	04 60/
60*	6 mo	Carbon monoxide/burns/smoke	Inhalation	Acc environ	31.5%
		inhalation			0.5.00
61*	14	Carbon monoxide	Inhalation	Int suicide	35.9%
62*	17	Carbon monoxide Carbon monoxide	Inhalation	Acc environ	35.9%
62* 63*	17 18	Carbon monoxide Carbon monoxide Carbon monoxide	Inhalation Inhalation	Acc environ Acc environ	
62* 63* 64*	17 18 20	Carbon monoxide Carbon monoxide Carbon monoxide Carbon monoxide	Inhalation Inhalation Inhalation	Acc environ Acc environ Int suicide	82.2%
62* 63* 64* 65*	17 18 20 21	Carbon monoxide Carbon monoxide Carbon monoxide Carbon monoxide Carbon monoxide Carbon monoxide	Inhalation Inhalation Inhalation Inhalation	Acc environ Acc environ Int suicide Int suicide	
62* 63* 64* 65* 66*	17 18 20 21 24	Carbon monoxide	Inhalation Inhalation Inhalation Inhalation Inhalation	Acc environ Acc environ Int suicide Int suicide Int suicide	82.2% 58.0%
62* 63* 64* 65* 66* 67*†	17 18 20 21 24 25	Carbon monoxide	Inhalation Inhalation Inhalation Inhalation Inhalation Inhalation	Acc environ Acc environ Int suicide Int suicide Int suicide Acc environ	82.2%
62* 63* 64* 65* 66* 67*† 68*	17 18 20 21 24 25 25	Carbon monoxide	Inhalation Inhalation Inhalation Inhalation Inhalation Inhalation Inhalation Inhalation	Acc environ Acc environ Int suicide Int suicide Int suicide Acc environ Acc environ	82.2% 58.0%
62* 63* 64* 65* 66* 67*† 68*	17 18 20 21 24 25 25 26	Carbon monoxide Carbon monoxide/smoke inh Carbon monoxide/smoke inh	Inhalation Inhalation Inhalation Inhalation Inhalation Inhalation Inhalation Inhalation Inhalation	Acc environ Acc environ Int suicide Int suicide Int suicide Acc environ Acc environ Acc environ	82.2% 58.0%
62* 63* 64* 65* 66* 67*† 68* 69	17 18 20 21 24 25 25 26 28	Carbon monoxide Carbon monoxide/smoke inh Carbon monoxide/smoke inh Carbon monoxide	Inhalation	Acc environ Acc environ Int suicide Int suicide Int suicide Acc environ Acc environ Acc environ Acc environ	82.2% 58.0% 44.0%, 1 hr
62* 63* 64* 65* 66* 67*† 68* 69 70 71*	17 18 20 21 24 25 25 26 28	Carbon monoxide Carbon monoxide/smoke inh Carbon monoxide/smoke inh Carbon monoxide Carbon monoxide Carbon monoxide	Inhalation	Acc environ Acc environ Int suicide Int suicide Int suicide Acc environ Acc environ Acc environ Acc environ Int suicide	82.2% 58.0% 44.0%, 1 hr 52.4%, 2–3 hr
62* 63* 64* 65* 66* 67*† 68* 69 70 71* 72*	17 18 20 21 24 25 25 26 28 28 36	Carbon monoxide Carbon monoxide/smoke inh Carbon monoxide Carbon monoxide Carbon monoxide Carbon monoxide Carbon monoxide Carbon monoxide	Inhalation	Acc environ Acc environ Int suicide Int suicide Int suicide Acc environ Acc environ Acc environ Acc environ Int suicide Int suicide Int suicide	82.2% 58.0% 44.0%, 1 hr 52.4%, 2–3 hr 44.4%
62* 63* 64* 65* 66* 67*† 68* 69 70 71* 72* 73*	17 18 20 21 24 25 25 26 28 28 36 37	Carbon monoxide Carbon monoxide/smoke inh Carbon monoxide/smoke inh Carbon monoxide Carbon monoxide Carbon monoxide Carbon monoxide Carbon monoxide Carbon monoxide	Inhalation	Acc environ Acc environ Int suicide Int suicide Int suicide Acc environ Acc environ Acc environ Acc environ Int suicide Int suicide Int suicide Acc environ	82.2% 58.0% 44.0%, 1 hr 52.4%, 2–3 hr
62* 63* 64* 65* 66* 67*† 68* 69 70 71* 72* 73* 74*	17 18 20 21 24 25 25 26 28 28 36 37 53	Carbon monoxide Carbon monoxide/smoke inh Carbon monoxide/smoke inh Carbon monoxide	Inhalation	Acc environ Acc environ Int suicide Int suicide Int suicide Acc environ Acc environ Acc environ Acc environ Int suicide Int suicide Int suicide Acc environ Int suicide Acc environ Int suicide	82.2% 58.0% 44.0%, 1 hr 52.4%, 2-3 hr 44.4% 54.8%
62* 63* 64* 65* 66* 67*† 68* 69 70 71* 72* 73* 74*	17 18 20 21 24 25 25 26 28 28 36 37 53 54	Carbon monoxide Carbon monoxide/smoke inh Carbon monoxide/smoke inh Carbon monoxide	Inhalation	Acc environ Acc environ Int suicide Int suicide Int suicide Acc environ Acc environ Acc environ Int suicide Int suicide Int suicide Int suicide Acc environ Int suicide Acc environ Int suicide Acc environ	82.2% 58.0% 44.0%, 1 hr 52.4%, 2–3 hr 44.4%
62* 63* 64* 65* 66* 67*† 68* 69 70 71* 72* 73* 74* 75‡ 76*	17 18 20 21 24 25 25 26 28 28 36 37 53 54	Carbon monoxide Carbon monoxide/smoke inh Carbon monoxide/smoke inh Carbon monoxide	Inhalation	Acc environ Acc environ Int suicide Int suicide Int suicide Acc environ Acc environ Acc environ Int suicide Int suicide Int suicide Acc environ Int suicide	82.2% 58.0% 44.0%, 1 hr 52.4%, 2-3 hr 44.4% 54.8%
62* 63* 64* 65* 66* 67*† 68* 69 70 71* 72* 73* 74*	17 18 20 21 24 25 25 26 28 28 36 37 53 54	Carbon monoxide Carbon monoxide/smoke inh Carbon monoxide/smoke inh Carbon monoxide	Inhalation	Acc environ Acc environ Int suicide Int suicide Int suicide Acc environ Acc environ Acc environ Int suicide Int suicide Int suicide Int suicide Acc environ Int suicide Acc environ Int suicide Acc environ	82.2% 58.0% 44.0%, 1 hr 52.4%, 2-3 hr 44.4% 54.8%
62* 63* 64* 65* 66* 67*† 68* 69 70 71* 72* 73* 74* 75‡ 76* 77* 78*	17 18 20 21 24 25 25 26 28 28 36 37 53 54 85 >17 20	Carbon monoxide Carbon monoxide/smoke inh Carbon monoxide/smoke inh Carbon monoxide	Inhalation	Acc environ Acc environ Int suicide Int suicide Int suicide Acc environ Acc environ Acc environ Int suicide Int suicide Int suicide Acc environ Int suicide	82.2% 58.0% 44.0%, 1 hr 52.4%, 2-3 hr 44.4% 54.8%
62* 63* 64* 65* 66* 67*† 68* 69 70 71* 72* 73* 74* 75‡ 76* 77* 78*	17 18 20 21 24 25 25 26 28 28 36 37 53 54 85 >17 20	Carbon monoxide Carbon monoxide/smoke inh Carbon monoxide/smoke inh Carbon monoxide	Inhalation	Acc environ Acc environ Int suicide Int suicide Int suicide Acc environ Acc environ Acc environ Int suicide Int suicide Int suicide Acc environ Acc gen Acc occup	82.2% 58.0% 44.0%, 1 hr 52.4%, 2-3 hr 44.4% 54.8%
62* 63* 64* 65* 66* 67*† 68* 69 70 71* 72* 73* 74* 75‡ 76* 77* 78*	17 18 20 21 24 25 25 26 28 28 36 37 53 54 85 >17 20 29 >17	Carbon monoxide Carbon monoxide/smoke inh Carbon monoxide/smoke inh Carbon monoxide	Inhalation	Acc environ Acc environ Int suicide Int suicide Int suicide Acc environ Acc environ Acc environ Int suicide Int suicide Int suicide Acc environ Int suicide Acc environ Int suicide Acc environ Int suicide Acc environ	82.2% 58.0% 44.0%, 1 hr 52.4%, 2-3 hr 44.4% 54.8%
62* 63* 64* 65* 66* 67*† 68* 69 70 71* 72* 73* 74* 75‡ 76* 77* 78*	17 18 20 21 24 25 25 26 28 28 36 37 53 54 85 >17 20 29 >17 >17	Carbon monoxide Carbon monoxide/smoke inh Carbon monoxide/smoke inh Carbon monoxide	Inhalation	Acc environ Acc environ Int suicide Int suicide Int suicide Acc environ Acc environ Acc environ Int suicide Int suicide Int suicide Acc environ Acc gen Acc occup	82.2% 58.0% 44.0%, 1 hr 52.4%, 2-3 hr 44.4% 54.8%
62* 63* 64* 65* 66* 67*† 68* 69 70 71* 72* 73* 74* 75‡ 76* 77* 78*	17 18 20 21 24 25 25 26 28 28 36 37 53 54 85 >17 20 29 >17	Carbon monoxide Carbon monoxide/smoke inh Carbon monoxide/smoke inh Carbon monoxide	Inhalation	Acc environ Acc environ Int suicide Int suicide Int suicide Acc environ Acc environ Acc environ Int suicide Int suicide Int suicide Acc environ Int suicide Acc environ Int suicide Acc environ Int suicide Acc environ	82.2% 58.0% 44.0%, 1 hr 52.4%, 2-3 hr 44.4% 54.8%

TABLE 15. Continued

Case	Age (yr)	Substances	Route of Exposure	Reason	Blood Levels**
Heavy metals					
83†‡	35	Copper	Ingestion	Int misuse	
See also ca		• •	· ·		
	se 150 (lead	<i>.</i>			
Herbicides	40	0.4.5	Immostica	Int outside	
84 05±	40	2,4-D	Ingestion	Int suicide Int suicide	
85†	30	Paraquat	Ingestion	Int suicide	
86	52 64	Paraquat	Ingestion Ingestion	Int suicide	
87† Hydrocarbons		Paraquat	nigestion	int suicide	
88†	79	Carbon tetrachloride	Ingestion	Int suicide	
89*	15	Freon	Inhalation	Acc misuse	
90*	23	Freon	Inhalation	Int suicide	
91*	15	Isobutane	Inhalation	Int unknown	
92†	12	Lamp oil	Ingestion	Acc gen	
93*†	13 mo	Mineral spirits	Ingestion	Acc gen	
93 ¦ 94	27	Toluene	Inhalation	Int abuse	
95*	15	Trichloroethane	Inhalation	int abuse	
55	.0	ethanol	Ingestion	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
96	53	Turpentine	Ingestion	Unknown	
		•	goodo	······	
See also ca	ses 194 (lig	hter fluid/naphtha); 7 (toluene).			
Insecticides a	nd pesticid	es			
97	70	Arsenic pesticide	Ingestion	Unknown	
98†	2	Aldicarb	Unknown	Acc gen	
99 [÷]	41	Diazinon	Ingestion	Int suicide	
100	57	Diazinon, malathion	Ingestion	Int suicide	
101†	41	Lindane	Ingestion	Unknown	. 1.3 μg/ml
102†	16	Methyl bromide	Inhalation	Acc environ	
103	6	Organophosphate	inhal + derm	Acc environ	
104	59	Phosphothioate aftershave (ethanol)	Ingestion	Int misuse	
105	24	Propoxur/pyrethrins/piperonyl butoxide combo	Paren + ing	Int suicide	
106†	13 mo	Sodium fluoride roach powder	Ing + dermal	Acc gen	
Paints and str	ipping age	nts			
107†	62	Combo with methanol/	Ingestion	Int suicide	104 mg/dl, 2 hr
		Acetone/			114 mg/dl, 2 hr
		Isopropanol/			101 mg/dl, 2 hr
		Methylene chloride			
See also ca	se 13 (pain	t).			
Plants		<u> </u>		1 11	
108*	26	Ambrosia artemisiifolia	Ingestion	Int unknown	
1001		cow parsnip	l	last alassas	
109†	>17	Marah oreganus seeds (tea)	Ingestion	Int abuse	
Radioisotope		Annan	labalation	A	
110*	32	Argon	Inhalation	Acc occup	
Rodenticides	35	Dradifacoure	Ingestion	Int abuse	
111†‡		Brodifacoum	Ingestion	Int abuse	
112*†	18 >17	Strychnine rodenticide	Ingestion Ingestion	Int suicide	
113*	<i>>17</i>	Strychnine rodenticide	ingestion	int suicide	
See also ca	se 402 (uni	known rodenticide).			
Analgesics					
114	20	Acetaminophen (adult)	Ingestion	Int suicide	45 μg/ml, 24 hi
115†	20	Acetaminophen (adult)	Ingestion	Int suicide	43 μg/ml, 24 m 67 μg/ml, >40
116	24	Acetaminophen (adult)	Ingestion	Int unknown	175 μg/ml, 4 hr
117†‡	25	Acetaminophen (adult)	Ingestion	Int misuse	22 μg/ml
1171+	25	Acetaminophen (adult)	Ingestion	Int suicide	172 μg/ml, 5 hr
119†	29	Acetaminophen (adult)	Ingestion	Int suicide	175 μg/ml, 13 h
120	63	Acetaminophen (adult)	Ingestion	Int suicide	65 μg/ml
	65	Acetaminophen	Ingestion	Unknown	739 μg/ml, 7 hr
121+			11140011011	O111111 O 11111	roo pogriii, r iii
121† 122	>17	Acetaminophen (adult)	Ingestion	Int suicide	>590 μg/ml, 20 hi

TABLE 15. Continued

Case	Age (yr)	Substances	Route of Exposure	Reason	Blood Levels**
123†	42	Acetaminophen (adult) acetone (nail polish remover)	Ingestion	Int suicide	3 μg/ml
124‡	60	Acetaminophen (adult)	Ingestion	Int unknown	45 μg/ml¶
125	41	Acetaminophen sleep-aid (diphenhydramine) temazepam	Ingestion	Int unknown	300 μg/ml, 12 hr
126	46	Acetaminophen/codeine	Ingestion	Int suicide	70 μg/ml, >12 hr [€]
127*	23	Acetaminophen/hydrocodone ethanol	Ingestion	Int suicide	60 μg/ml, ≤4 hr¶
128†	65	Acetaminophen/oxycodone	Ingestion	Int suicide	1,000 μg/ml, 6–12 hr¶
129*	19	Acetaminophen/propoxyphene	Ingestion	Int abuse Propoxyphene Norpropoxyphene	42 μg/ml§¶ 2.8 μg/ml§ 13.5 μg/ml§
130‡	26	Acetaminophen/propoxyphene	Ingestion	Int suicide	216 μg/ml¶
131 [*]	39	Acetaminophen/propoxyphene	Unknown	Unknown	· =
132‡	42	Acetaminophen/propoxyphene acetaminophen (adult)	Ingestion	Int misuse	56 μg/m l €
133	59	Acetaminophen/propoxyphene	Ingestion	Int suicide	491 μg/ml¶
134	66	Acetaminophen/propoxyphene	Ingestion	Int suicide	9 μg/ml ^e
		" the above Above	3	Norpropoxyphene	315 ng/ml
		Acetaminophen/codeine		Codeine	0.2 μg/ml
135	14	Aspirin (adult)	Ingestion	Int suicide	90 mg/dl, 14 hr
136	24	Aspirin (adult)	Ingestion	Unknown	125 mg/dl
		· · · · · · · · · · · · · · · · · · ·	_		
137	32	Aspirin	Ingestion	Int suicide	111 mg/dl, 3 hr
138	44	Aspirin	Ingestion	Int suicide	125 mg/dl
139	48	Aspirin (adult)	Ingestion	Int suicide	144 mg/dl
140	51	Aspirin	Ingestion	Int suicide	131 mg/dl
141	54	Aspirin	Ingestion	Int suicide	85 mg/dl, 11 hr
142	70	Aspirin (adult)	Ingestion	Int suicide	
143	71	Aspirin	Ingestion	Int suicide	79 mg/dl
144	72	Aspirin (adult)	Ingestion	Int suicide	62 mg/dl
145‡	63	Aspirin	Ingestion	Int suicide	21 mg/dl
1404	00	•	ingestion	int suicide	_
4.401	07	acetaminophen (adult)	1	1-4	92 μg/ml
146‡	37	Aspirin	Ingestion	Int misuse	65 mg/dl
		acetaminophen/oxycodone			<8 μg/ml¶
147‡	37	Aspirin cimetidine	Ingestion	Int misuse	90 mg/dl
148	20	Aspirin	Ingestion	Int suicide	100 mg/dl
	•	diphenhydramine			
149	22	Aspirin (adult) diphenhydramine	Ingestion	Int unknown	100 mg/dl
150	54	Aspirin (adult) ethanol	Ingestion	Int suicide	130 mg/dl, 12-15 hi 170 mg/dl, 12-15 hi
151	66	Aspirin (adult) lead (buckshot)	Ingestion	Int suicide	59 mg/dl
152	64	Aspirin (adult) loxapine	Ingestion	Int suicide	90 mg/dl
153†	23	Aspirin methylene blue Rush (isobutyl nitrate)	Ing + paren	Int unknown	115 mg/dl
154*	30	Aspirin/butalbital/codeine	Ingestion	Int unknown	
155	25	Aspirin/carisiprodol	Ingestion	Int suicide	
		Codeine			0.62a/mis
156	57	diazepam acetaminophen	Ingestion	Unknown	0.63 μg/ml§ 0.78 μg/ml§# 11 μg/ml§
157†	57	Colchicine	Ingestion	Int suicide	
158*	62	Colchicine	Ingestion	Adv rxn	
159†	78 > 17	Colchicine	Ingestion	Acc misuse	• .
160*	>17	Fentanyl diazepam	Parenteral	Int suicide	
161	>17	Indomethacin	Ingestion	Int unknown	
162*	34	Methadone	Ingestion	Int abuse	0.22 μg/mi§

TABLE 15. Continued

(aspirin/ 315, 350 phene); 3 3 31 s 196, 25	Substances Methadone Methadone triazolam Morphine sympathomimetic Opiate Pentazocine Propoxyphene Propoxyphene cocaine dextromethorphan Propoxyphene diazepam Propoxyphene ethanol Sufentanil cetaminophen); 342, 343, 383 (acetami dihydrocodone); 203, 290 (aspirin/oxyo (diflunisal); 245, 302 (ibuprofen); 227 330 (salsalate). Benztropine amphetamine 50 (benztropine). Carbamazepine	codone); 313 (aspirin/pro	Int suicide Int abuse Int abuse Int suicide Int suicide Int suicide Int abuse Int abuse Norpropoxyphe Nordiazep Int suicide	poxyphene); 190, 327 codeine); 197 ne); 193, 358 (opiate); 19 µg/ml§
39 17 15 15 29 28 37 17 33 s 190 (ac (aspirin/ 115, 350 shene); 3 s 31 s 196, 25	Methadone triazolam Morphine sympathomimetic Opiate Pentazocine Propoxyphene Propoxyphene Propoxyphene cocaine dextromethorphan Propoxyphene diazepam Propoxyphene ethanol Sufentanil setaminophen); 342, 343, 383 (acetamidihydrocodone); 203, 290 (aspirin/oxyo (diflunisal); 245, 302 (ibuprofen); 227 330 (salsalate). Benztropine amphetamine	Ingestion Parenteral Parenteral Ingestion Ingestion Ingestion Ingestion Ingestion Ingestion Ingestion Ingestion Parenteral Inophen/codeine); 192, 2 Indomethacin); 315 (median)	Int suicide Int abuse Int abuse Int suicide Int suicide Int suicide Int abuse Int abuse Norpropoxyphe Nordiazep Int suicide	12.5 μg/ml 12.5 μg/ml 4,500 ng/ml 1,021 ng/ml 2,786 ng/ml 1.67 μg/ml am 62.9 μg/ml poxyphene); 190, 327 codeine); 197 ne); 193, 358 (opiate);
17 nk 51 15 29 28 37 17 33 s 190 (ac (aspirin/ 315, 350 shene); 3 s 31 s 196, 25	triazolam Morphine sympathomimetic Opiate Pentazocine Propoxyphene Propoxyphene Propoxyphene cocaine dextromethorphan Propoxyphene diazepam Propoxyphene ethanol Sufentanil cetaminophen); 342, 343, 383 (acetamidihydrocodone); 203, 290 (aspirin/oxyoldiflunisal); 245, 302 (ibuprofen); 227 330 (salsalate). Benztropine amphetamine 50 (benztropine).	Parenteral Parenteral Ingestion Ingestion Ingestion Ingestion Ingestion Ingestion Parenteral nophen/codeine); 192, 2 codone); 313 (aspirin/pro (indomethacin); 315 (me	Int suicide Int abuse Int abuse Int suicide Int suicide Int suicide Int abuse Int abuse Norpropoxyphe Nordiazep Int suicide	12.5 µg/ml 4,500 ng/ml 1,021 ng/ml ene 2,786 ng/ml 1.67 µg/ml am 62.9 µg/ml poxyphene); 190, 327 codeine); 197 ne); 193, 358 (opiate);
17 nk 51 15 29 28 37 17 33 s 190 (ac (aspirin/ 315, 350 shene); 3 s 31 s 196, 25	triazolam Morphine sympathomimetic Opiate Pentazocine Propoxyphene Propoxyphene Propoxyphene cocaine dextromethorphan Propoxyphene diazepam Propoxyphene ethanol Sufentanil cetaminophen); 342, 343, 383 (acetamidihydrocodone); 203, 290 (aspirin/oxyoldiflunisal); 245, 302 (ibuprofen); 227 330 (salsalate). Benztropine amphetamine 50 (benztropine).	Parenteral Parenteral Ingestion Ingestion Ingestion Ingestion Ingestion Ingestion Parenteral nophen/codeine); 192, 2 codone); 313 (aspirin/pro (indomethacin); 315 (me	Int abuse Int abuse Int suicide Int suicide Int suicide Int abuse Int abuse Norpropoxyphe Nordiazep Int suicide	4,500 ng/ml 1,021 ng/ml 2,786 ng/ml 1.67 μg/ml 3.67 μg/ml 4,500 ng/ml 1.67 μg/ml 2,786 ng/ml 2,786 ng/ml 2,796 ng/ml 2,797 ng/ml 3,358 (opiate); 19 μg/ml§
nk 51 15 29 28 37 17 33 s 190 (ac (aspirin/ 315, 350 shene); 3 s 31 s 196, 25	Morphine sympathomimetic Opiate Pentazocine Propoxyphene Propoxyphene Propoxyphene cocaine dextromethorphan Propoxyphene diazepam Propoxyphene ethanol Sufentanil cetaminophen); 342, 343, 383 (acetamidihydrocodone); 203, 290 (aspirin/oxyo (diflunisal); 245, 302 (ibuprofen); 227 330 (salsalate). Benztropine amphetamine 50 (benztropine).	Parenteral Ingestion Ingestion Ingestion Ingestion Ingestion Ingestion Parenteral nophen/codeine); 192, 2 codone); 313 (aspirin/pro (indomethacin); 315 (me	Int abuse Int suicide Int suicide Int suicide Int abuse Int abuse Norpropoxyphe Nordiazep Int suicide	4,500 ng/ml 1,021 ng/ml 2,786 ng/ml 1.67 μg/ml 3.67 μg/ml 4,500 ng/ml 1.67 μg/ml 2,786 ng/ml 2,786 ng/ml 2,796 ng/ml 2,797 ng/ml 3,358 (opiate); 19 μg/ml§
nk 51 15 29 28 37 17 33 s 190 (ac (aspirin/ 315, 350 shene); 3 s 31 s 196, 25	sympathomimetic Opiate Pentazocine Propoxyphene Propoxyphene Propoxyphene cocaine dextromethorphan Propoxyphene diazepam Propoxyphene ethanol Sufentanil setaminophen); 342, 343, 383 (acetamidihydrocodone); 203, 290 (aspirin/oxyo (diflunisal); 245, 302 (ibuprofen); 227 330 (salsalate). Benztropine amphetamine 50 (benztropine).	Parenteral Ingestion Ingestion Ingestion Ingestion Ingestion Ingestion Parenteral nophen/codeine); 192, 2 codone); 313 (aspirin/pro (indomethacin); 315 (me	Int abuse Int suicide Int suicide Int suicide Int abuse Int abuse Norpropoxyphe Nordiazep Int suicide	4,500 ng/ml 1,021 ng/ml 2,786 ng/ml 1.67 μg/ml 3.67 μg/ml 4,500 ng/ml 1.67 μg/ml 4,500 ng/ml 1.67 μg/ml 5,190, 327 6,20 μg/ml 6,327 6,32
51 15 29 28 37 17 33 s 190 (ac (aspirin/ 315, 350 shene); 3 s 31 s 196, 25	Opiate Pentazocine Propoxyphene Propoxyphene Propoxyphene cocaine dextromethorphan Propoxyphene diazepam Propoxyphene ethanol Sufentanil setaminophen); 342, 343, 383 (acetamidihydrocodone); 203, 290 (aspirin/oxyo (diflunisal); 245, 302 (ibuprofen); 227 330 (salsalate). Benztropine amphetamine 50 (benztropine).	Ingestion Ingestion Ingestion Ingestion Ingestion Ingestion Parenteral nophen/codeine); 192, 2 codone); 313 (aspirin/prodindomethacin); 315 (mediate)	Int suicide Int suicide Int suicide Int abuse Int abuse Nordiazep Int suicide	4,500 ng/ml 1,021 ng/ml 2,786 ng/ml 1.67 μg/ml 2,62.9 μg/ml 2,786 ng/ml 3,67 μg/ml 4,500 ng/ml 2,786 ng/ml 2,786 ng/ml 2,786 ng/ml 2,786 ng/ml
15 29 28 37 17 33 s 190 (ac (aspirin/ 115, 350 shene); 3 s 31 s 196, 25	Propoxyphene Propoxyphene Propoxyphene cocaine dextromethorphan Propoxyphene diazepam Propoxyphene ethanol Sufentanil cetaminophen); 342, 343, 383 (acetamidihydrocodone); 203, 290 (aspirin/oxyo (diflunisal); 245, 302 (ibuprofen); 227 330 (salsalate). Benztropine amphetamine 50 (benztropine).	Ingestion Ingestion Ingestion Ingestion Ingestion Parenteral nophen/codeine); 192, 2 codone); 313 (aspirin/pro (indomethacin); 315 (me	Int suicide Int suicide Int abuse Int abuse Norpropoxyphe Nordiazep Int suicide Int suicide 33 (acetaminophen/pro ppoxyphene); 340, 391 (eperidine); 198 (morphii	4,500 ng/ml 1,021 ng/ml 2,786 ng/ml 1.67 μg/ml 2,62.9 μg/ml 2,786 ng/ml 3,67 μg/ml 4,500 ng/ml 2,786 ng/ml 3,67 μg/ml 4,500 ng/ml
29 28 37 17 33 s 190 (ac (aspirin/ 115, 350 shene); 3 s 31 s 196, 25	Propoxyphene Propoxyphene cocaine dextromethorphan Propoxyphene diazepam Propoxyphene ethanol Sufentanil cetaminophen); 342, 343, 383 (acetami dihydrocodone); 203, 290 (aspirin/oxyo (diflunisal); 245, 302 (ibuprofen); 227 330 (salsalate). Benztropine amphetamine 50 (benztropine).	Ingestion Ingestion Ingestion Ingestion Parenteral nophen/codeine); 192, 2 codone); 313 (aspirin/pro (indomethacin); 315 (me	Int suicide Int abuse Int abuse Nordiazep Int suicide Int suicide 33 (acetaminophen/pro ppoxyphene); 340, 391 (eperidine); 198 (morphii	1,021 ng/ml ene 2,786 ng/ml 1.67 µg/ml am 62.9 µg/ml poxyphene); 190, 327 codeine); 197 ne); 193, 358 (opiate);
28 37 17 33 s 190 (ac (aspirin/ 315, 350 shene); 3 s 31 s 196, 25	Propoxyphene cocaine dextromethorphan Propoxyphene diazepam Propoxyphene ethanol Sufentanil cetaminophen); 342, 343, 383 (acetami dihydrocodone); 203, 290 (aspirin/oxyo (diflunisal); 245, 302 (ibuprofen); 227 330 (salsalate). Benztropine amphetamine 50 (benztropine).	Ingestion Ingestion Ingestion Parenteral nophen/codeine); 192, 2 codone); 313 (aspirin/pro (indomethacin); 315 (me	Int abuse Int abuse Nordiazep Int suicide Int suicide 33 (acetaminophen/propoxyphene); 340, 391 (eperidine); 198 (morphii	ene 2,786 ng/ml 1.67 μg/ml am 62.9 μg/ml poxyphene); 190, 327 codeine); 197 ne); 193, 358 (opiate);
37 33 s 190 (a(aspirin/ 115, 350 shene); 3 s 31 s 196, 25	cocaine dextromethorphan Propoxyphene diazepam Propoxyphene ethanol Sufentanil cetaminophen); 342, 343, 383 (acetami dihydrocodone); 203, 290 (aspirin/oxyo (diffunisal); 245, 302 (ibuprofen); 227 330 (salsalate). Benztropine amphetamine 50 (benztropine).	Ingestion Ingestion Parenteral nophen/codeine); 192, 2 codone); 313 (aspirin/pro (indomethacin); 315 (me	Int abuse Nordiazep Int suicide Int suicide 33 (acetaminophen/propoxyphene); 340, 391 (eperidine); 198 (morphii	ene 2,786 ng/ml 1.67 μg/ml am 62.9 μg/ml poxyphene); 190, 327 codeine); 197 ne); 193, 358 (opiate);
17 33 s 190 (ac (aspirin/ 315, 350 shene); 3 s 31 s 196, 25	dextromethorphan Propoxyphene diazepam Propoxyphene ethanol Sufentanil cetaminophen); 342, 343, 383 (acetami dihydrocodone); 203, 290 (aspirin/oxyo (diflunisal); 245, 302 (ibuprofen); 227 330 (salsalate). Benztropine amphetamine 50 (benztropine).	Ingestion Parenteral nophen/codeine); 192, 2 codone); 313 (aspirin/pro (indomethacin); 315 (me	Norpropoxyphe Nordiazep Int suicide Int suicide 33 (acetaminophen/pro ppoxyphene); 340, 391 (eperidine); 198 (morphii	ene 2,786 ng/ml 1.67 μg/ml am 62.9 μg/ml poxyphene); 190, 327 codeine); 197 ne); 193, 358 (opiate); 19 μg/ml§
17 33 s 190 (ac (aspirin/ 315, 350 shene); 3 s 31 s 196, 25	Propoxyphene diazepam Propoxyphene ethanol Sufentanil setaminophen); 342, 343, 383 (acetami dihydrocodone); 203, 290 (aspirin/oxyo (diflunisal); 245, 302 (ibuprofen); 227 330 (salsalate). Benztropine amphetamine 50 (benztropine).	Ingestion Parenteral nophen/codeine); 192, 2 codone); 313 (aspirin/pro (indomethacin); 315 (me	Norpropoxyphe Nordiazep Int suicide Int suicide 33 (acetaminophen/pro ppoxyphene); 340, 391 (eperidine); 198 (morphii	ene 2,786 ng/ml 1.67 μg/ml am 62.9 μg/ml poxyphene); 190, 327 codeine); 197 ne); 193, 358 (opiate); 19 μg/ml§
17 33 s 190 (ac (aspirin/ 315, 350 shene); 3 s 31 s 196, 25	diazepam Propoxyphene ethanol Sufentanil cetaminophen); 342, 343, 383 (acetami dihydrocodone); 203, 290 (aspirin/oxyo (diflunisal); 245, 302 (ibuprofen); 227 330 (salsalate). Benztropine amphetamine 50 (benztropine).	Ingestion Parenteral nophen/codeine); 192, 2 codone); 313 (aspirin/pro (indomethacin); 315 (me	Norpropoxyphe Nordiazep Int suicide Int suicide 33 (acetaminophen/pro ppoxyphene); 340, 391 (eperidine); 198 (morphii	ene 2,786 ng/ml 1.67 μg/ml am 62.9 μg/ml poxyphene); 190, 327 codeine); 197 ne); 193, 358 (opiate); 19 μg/ml§
33 s 190 (ad (aspirin/ 315, 350 ohene); 3 s 31 s 196, 25	Propoxyphene ethanol Sufentanil cetaminophen); 342, 343, 383 (acetami dihydrocodone); 203, 290 (aspirin/oxyo (diflunisal); 245, 302 (ibuprofen); 227 330 (salsalate). Benztropine amphetamine 50 (benztropine).	Parenteral nophen/codeine); 192, 2 codone); 313 (aspirin/pro (indomethacin); 315 (me Ingestion	Nordiazep Int suicide Int suicide 33 (acetaminophen/pro ppoxyphene); 340, 391 (eperidine); 198 (morphii Int unknown	1.67 μg/ml am 62.9 μg/ml poxyphene); 190, 327 codeine); 197 ne); 193, 358 (opiate); 19 μg/ml§
33 s 190 (ad (aspirin/ 315, 350 ohene); 3 s 31 s 196, 25	Propoxyphene ethanol Sufentanil cetaminophen); 342, 343, 383 (acetami dihydrocodone); 203, 290 (aspirin/oxyo (diflunisal); 245, 302 (ibuprofen); 227 330 (salsalate). Benztropine amphetamine 50 (benztropine).	Parenteral nophen/codeine); 192, 2 codone); 313 (aspirin/pro (indomethacin); 315 (me Ingestion	Int suicide Int suicide 33 (acetaminophen/pro ppoxyphene); 340, 391 (eperidine); 198 (morphii Int unknown	am 62.9 μg/ml poxyphene); 190, 327 codeine); 197 ne); 193, 358 (opiate); 19 μg/ml§
33 s 190 (ad (aspirin/ 315, 350 ohene); 3 s 31 s 196, 25	ethanol Sufentanil setaminophen); 342, 343, 383 (acetami dihydrocodone); 203, 290 (aspirin/oxyd (diflunisal); 245, 302 (ibuprofen); 227 330 (salsalate). Benztropine amphetamine 50 (benztropine).	Parenteral nophen/codeine); 192, 2 codone); 313 (aspirin/pro (indomethacin); 315 (me Ingestion	Int suicide 33 (acetaminophen/pro ppoxyphene); 340, 391 (eperidine); 198 (morphii Int unknown	codeine); 197 ne); 193, 358 (opiate); 19 µg/ml§
s 190 (ac (aspirin/ 315, 350 ohene); 3 3 31 s 196, 25	Sufentanil cetaminophen); 342, 343, 383 (acetami dihydrocodone); 203, 290 (aspirin/oxyd (diflunisal); 245, 302 (ibuprofen); 227 330 (salsalate). Benztropine amphetamine 50 (benztropine).	nophen/codeine); 192, 2 codone); 313 (aspirin/pro (indomethacin); 315 (me Ingestion	33 (acetaminophen/pro ppoxyphene); 340, 391 (eperidine); 198 (morphii Int unknown	codeine); 197 ne); 193, 358 (opiate); 19 µg/ml§
s 190 (ac (aspirin/ 315, 350 ohene); 3 3 31 s 196, 25	cetaminophen); 342, 343, 383 (acetamidihydrocodone); 203, 290 (aspirin/oxyd (diflunisal); 245, 302 (ibuprofen); 227 330 (salsalate). Benztropine amphetamine	nophen/codeine); 192, 2 codone); 313 (aspirin/pro (indomethacin); 315 (me Ingestion	33 (acetaminophen/pro ppoxyphene); 340, 391 (eperidine); 198 (morphii Int unknown	codeine); 197 ne); 193, 358 (opiate); 19 µg/ml§
(aspirin/ 315, 350 phene); 3 3 31 s 196, 25	dihydrocodone); 203, 290 (aspirin/oxyd (diflunisal); 245, 302 (ibuprofen); 227 330 (salsalate). Benztropine amphetamine 50 (benztropine).	codone); 313 (aspirin/pro (indomethacin); 315 (me Ingestion	ppoxyphene); 340, 391 (eperidine); 198 (morphii Int unknown	codeine); 197 ne); 193, 358 (opiate); 19 µg/ml§
31 s 196, 25 2 [.]	50 (benztropine).	Ü		
s 196, 25 2 [.]	50 (benztropine).	Ü		
2·	• •	Ingestion	Acc gen	
2·	Carbamazepine	Ingestion	Acc gen	
	Carbamazepine	ingestion	Acc gen	
7 (2)	Carbamazepine	Ingestion	Int suicide	120a/ml / hr
19 34	Carbamazepine	Ingestion	Acc unknown	120 μg/ml, 4 hr 55 μg/ml
38	Carbamazepine	Ingestion	Int suicide	ου μα
	amitriptyline	9	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
3	Phenytoin	Ingestion	Acc gen	50 μg/ml, <4 h
;				
17	Amitriptyline	Ingestion	Int suicide	
29	Amitriptyline	Ingestion	Int suicide	203 ng/ml
32	Amitriptyline	Ingestion	Int suicide	4 044
46	Amitriptyline	Ingestion	Int suicide	1,311 ng/ml
47	Amitriptyline	Ingestion	Int suicide	ine 625 ng/ml
		•		
48				
59				1,582 ng/ml#
59	Amitriptyline	Ingestion	Int suicide	3,389 ng/ml
			Nortriptyl	ine 533 ng/ml
68	Amitriptyline	Ingestion	Int suicide	1,200 ng/ml§#
67	Amitriptyline	Ingestion	Int suicide	
				103 μg/ml, 12 hr
40	, , ,	· Inmedian	lmt avviolata	60 mg/dl, 12 hr
40		ingestion	int suicide	
42	•	Ingestion	Int suicide	
	the state of the s	mgodion	in saidae	
	acetaminophen/propoxyphene			
34	Amitriptyline	Ingestion	Int suicide	
	ethanol	-		180 mg/dl, 3-5 h
	opiate			
18	Amitriptyline	Ingestion	Int suicide	
	lighter fluid/naphtha			
	•	4	Amalan da da da	
05	Amitriptyline	Ingestion	int suicide	
4 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	59 59 68 67 40 42	Amitriptyline Amitriptyline Amitriptyline Amitriptyline Amitriptyline Amitriptyline Amitriptyline Amitriptyline Acetaminophen (adult) Aspirin (adult) Amitriptyline Alprazolam Amitriptyline Alprazolam Acetaminophen/propoxyphene Amitriptyline ethanol opiate Amitriptyline lighter fluid/naphtha flurazepam Amitriptyline	Amitriptyline Ingestion Acetaminophen (adult) Aspirin (adult) Amitriptyline Ingestion Alprazolam Amitriptyline Ingestion Alprazolam Acetaminophen/propoxyphene Amitriptyline Ingestion Amitriptyline Ingestion Amitriptyline Ingestion Amitriptyline Ingestion Amitriptyline Ingestion ethanol opiate Amitriptyline Ingestion	Amitriptyline Ingestion Int suicide Amitriptyline Ingestion Int unknown Amitriptyline Ingestion Int suicide Acetaminophen (adult) Amitriptyline Ingestion Int suicide Aprazolam Amitriptyline Ingestion Int suicide Ethanol Opiate Amitriptyline Ingestion Int suicide

TABLE 15. Continued

Route of Exposure	Reason	Blood Levels**
Ingestion	Int suicide	
·	1	
Ingestion	Int suicide	
		4.0 mEq/L
Ingestion	Unknown	
Ingestion	Int suicide	28,000 ng/ml
		19,000 ng/ml
Ingestion	Int suicide	
Ingestion	Int suicide	
Ingestion	Int suicide	
Ingestion	Int suicide	390 ng/ml#
Ingestion	Int suicide	
Ingestion	Int suicide	
Ingestion	Int suicide	
Ingestion	Int suicide	4,200 ng/ml§
Ingestion	Int suicide	1,334 ng/ml, >4
Ingestion	Int suicide	2,518 ng/ml
Ingestion	Int suicide	
Ingestion	Int suicide	
Ingestion	Unknown	
Ingestion	Int suicide	1,145 ng/ml
Ingestion	Int misuse	
Ingestion	Int suicide	
Ingestion	Int suicide	
Ingestion	Int suicide	1,936 ng/ml
Ingestion	Int suicide	
Ingestion	Int suicide	1,960 ng/ml
Ingestion	Int suicide	
Ingestion	Int unknown	
Ingestion	Int suicide	
Ingestion	Int suicide	
	Ψ,	
Ingestion	Int suicide	3,885 ng/ml
Ingestion	Int suicide	
Ingestion	Int suicide	9,900 ng/ml§
	Nordoxepii	
Ingestion	Int suicide	3,413 ng/ml
	Nordoxepii	n 243 ng/ml
Ingestion	Int suicide	
Ingestion	Int suicide	•
hene		
t	Ingestion	Ingestion Int suicide

TABLE 15. Continued

Case	Age (yr)	Substances	Route of Exposure	Reason	Blood Levels**
234	43	Doxepin desipramine	Ingestion	Int suicide	
235	35	Doxepin diphenhydramine	Ingestion	Int suicide	8,500 ng/ml§ 4.1 µg/ml§
236*	27	Doxepin ethanol	Ingestion	Int suicide	1,300 ng/ml
237*	30	Doxepin . ethanol	Ingestion	Int suicide Nordoxepin	1,400 ng/ml§ 500 ng/ml§ 300 mg/dl§
238	38	Doxepin metoprolol ethanol	Ingestion	Int suicide	233 mg/dl
239*	30	Doxepin phenobarbital	Ingestion	Int suicide	75.3 μg/ml
240*	31	Imipramine	Ingestion	Int suicide	75.5 μg/iiii
240	34	· · · · · · · · · · · · · · · · · · ·	•	Int suicide	4,210 ng/ml§
241 242*	3 4 36	Imipramine	Ingestion Ingestion	Int suicide	4,210 hg/img
242 243*		Imipramine	=		
	45 00	Imipramine	Ingestion	Int suicide	1 070 na/ml
244‡ 245	80 14	Imipramine Imipramine alprazolam ibuprofen	Ingestion Ingestion	Acc misuse Int suicide	1,078 ng/ml
246	25	Imipramine chloral hydrate loxapine	Ingestion	Int suicide	
247	20	Imipramine clorazepate	Ingestion	Int suicide	
248*	50	Imipramine diazepam	Ingestion	Int suicide	
249	33	Imipramine ethanol	Ingestion	Int suicide	
250	19	Imipramine	Ingestion	Int suicide Desipramine	5,210 ng/ml§ 4,040 ng/ml§
		perphenazine benztropine			
251	53	Imipramine thioridazine mesoridazine	Ingestion	Int suicide	
252†	64	Lithium	Ingestion	Int suicide	8.5 mEq/L
253‡	70	Lithium	Ingestion	Unknown	2.7 mEg/L
254	38	Loxapine	Ingestion	Int suicide	
255	49	Loxapine	Ingestion	Unknown	
256	58	Loxapine	Ingestion	Int suicide	
257	52	Maprotiline amitriptyline/perphenazine	Ingestion	Int suicide	
258	64	Nortriptyline desipramine doxepin	Ingestion	Int suicide	
259	22	Phenelzine	Ingestion	Int suicide	
260†	24	Phenelzine	Ingestion	Int suicide	
261†	39	Phenelzine	Ingestion	Int suicide	140 ng/ml§
262	54	Phenelzine alprazolam	Ingestion	Int suicide	•
263†	44	Tranylcypromine	Ingestion	Int suicide	
264	30	Tranylcypromine I-thyroxine flurazepam	Ingestion	Int suicide	
265†	67	Trazodone digoxin	Ingestion	Int suicide	5,800 ng/ml 2.0 ng/ml
26 6	66	Unk cyclic antidepressant	Ingestion	Unknown	· ·

See also cases 178, 316 (amitriptyline); 314 (amitriptyline/perphenazine); 348 (desipramine); 325 (lithium); 152 (loxapine); 338 (maprotiline); 293 (nortriptyline); 310 (trazodone).

TABLE 15. Continued

Antihistamines 267† See also cas Antimicrobials 268 269*† Antineoplastics 270	15 es 147 (cin 1 mo 12 mo s 24	Diphenhydramine netidine); 148, 149, 235, 355, 394 (diphenh Chloramphenicol (100-fold dosing error) Chloroquine	Ingestion nydramine). Parenteral	Int suicide	9.7 μg/ml§
See also cas Antimicrobials 268 269*† Antineoplastics	es 147 (cin 1 mo 12 mo s 24	netidine); 148, 149, 235, 355, 394 (diphenh Chloramphenicol (100-fold dosing error)	nydramine).		9.7 μg/ml§
Antimicrobials 268 269*† Antineoplastics	1 mo 12 mo 3 24	Chloramphenicol (100-fold dosing error)			
268 269*† Antineoplastics	12 mo s 24	error)	Parenteral		
269*† Antineoplastics	12 mo s 24	error)	Parenteral		
Antineoplastics	s 24	Chloroquine -		Acc misuse	
•	24	·	Ingestion	Acc gen	
		Methotrexate (3 grams)	Parenteral	Acc misuse	
Asthma therap	ies	Methotrexate (5 grains)	raienterai	Acc misuse	
271†‡	6 mo	Theophylline	Ingestion	Acc misuse	40 μg/ml
272‡	2	Theophylline	Ingestion	Acc misuse	41 μg/ml
273†	15	Theophylline (long-acting)	Ingestion	Int suicide	190 μg/ml
274†	17	Theophylline (long-acting)	Ingestion	Int suicide	117 μg/ml
275	28	Theophylline	Ingestion	Int suicide	108 μg/ml, 4 hr
276	44	Theophylline	Ingestion	Int suicide	160 μg/ml, 1–3 h
277	62	Theophylline	Ingestion	Int suicide	50 μg/ml, 2 hr
278‡	65	Theophylline (long-acting)	Ingestion	Acc misuse	60 μg/ml
279‡	70	Theophylline (long-acting)	Ingestion	Unknown	53 μg/ml
280‡	70	Theophylline (long-acting)	Ingestion	Acc gen	40 μg/ml
281‡	71	Theophylline	Ingestion	Int unknown	120 μg/ml
282‡	72	Theophylline	Parenteral	Acc misuse	65 μg/ml
283‡	76	Theophylline	Ingestion	Unknown	72 μg/ml
284‡	77	Theophylline (long-acting)	Ingestion	Acc gen	36 μg/ml
285‡	81	Theophylline (long-acting)	Ingestion	Acc misuse	64 μg/ml
286‡	83	Theophylline	Ingestion	Acc misuse	40 μg/ml
287	73	Theophylline (long-acting)	Ingestion	Int suicide	82 μg/ml
207	70	digoxin	nigestion	in saicide	5.6 ng/ml
288†‡	72	Theophylline	Ingestion	Int misuse	40 μg/ml
2001+	12	ethchlorvynol	ingestion	int illisuse	40 μg/1111
289‡	51	Theophylline (long-acting) phenylpropanolamine	Ingestion	Acc gen	57 μg/ml 4.7 μg/ml§
See also cas	es 202, 300	6 (theophylline).			wg3
0					
Cardiovascula	_				
290*	55	Acebutolol aspirin/oxycodone ethanol	Ingestion	Int suicide	
291†	65	Amiodarone	Ingestion	Unknown	14 μg/ml
292	15	Atenolol	Ingestion	Int suicide	, , mg,
		diltiazem	mgoonon	50.0.00	
293*	27	Captopril	Ingestion	Int suicide	
		nortriptyline	9****		1,400 ng/ml
		flurazepam			90 ng/ml
294†	63	Captopril	Ingestion	Int suicide	
		ethanol	900		238 mg/dl§
295	4	Digoxin	Ingestion	Acc gen	====g, =g
296†	54	Digoxin	Ingestion	Int suicide	30.8 ng/ml, 2 hr
297‡	70	Digoxin	Ingestion	Acc misuse	5 ng/ml
298	71	Digoxin	Ingestion	Acc unknown	3.4 ng/ml
299†	79	Digoxin	Ingestion	Int suicide	24.9 ng/ml
300‡	91	Digoxin	Ingestion	Int unknown	3.4 ng/ml
301	34	Digoxin aspirin/dihydrocodone	Ingestion	Int suicide	6 ng/ml, 10 hr
302	70	Digoxin ibuprofen	Ingestion	Int suicide	9.8 ng/ml
303†	78	Digoxin	Ingestion	Unknown	3.9 ng/ml
304†	48	methyldopa Digoxin metoprolol	Ingestion	Int suicide	10 ng/ml

TABLE 15. Continued

Case	Age (yr)	Substances	Route of Exposure	Reason	Blood Levels**
305	58	Digoxin	Ingestion	Int suicide	
		propranolol	Ū		
		diazepam			
306‡	65	Digoxin	Ingestion	Int misuse	12 ng/ml
		theophylline (long-acting)		•	35 μg/ml
307*	90	Digoxin	Ingestion	Int suicide	
		triazolam			
308	16	Diltiazem	Ingestion	Int suicide	5,500 ng/ml
309	, 40	Disopyramide	Ingestion	Int suicide	
		trifluoperazine			
310	25	Disopyramide	Ingestion	Int suicide	
		metoprolol	•		
		trazodone			
311*	29	Encainide	Ingestion	Int suicide	
312†	21	Flecainide	Ingestion	Int suicide	10.9 μg/ml§
		propranolol			1.1 μg/ml§
313	68	Methyldopa			
		aspirin/propoxyphene	Ingestion	Int suicide	04.0 / 10
314	32	Metoproiol	Ingestion	Int suicide	24.3 μg/ml§
		amitriptyline/perphenazine		At a Contract	510 ng/ml§
				Nortriptyline	210 ng/ml§
045	40	amphetamine	1	to a contact dia	
315	42	Metoprolol	Ingestion	Int suicide	
		diflunisal			
040		meperidine	la mantina	lus acciainta	0.0 a/m16
316	64	Metoprolol	Ingestion	Int suicide	0.3 μg/ml§
		amitriptyline			110 ng/ml§#
017	00	prazosin Nifedinina	Ingostion	Int aviaida	
317	22	Nifedipine	Ingestion	Int suicide	
	•	propranolol clonidine			
318	52	Procainamide	Ingestion	Int suicide	
310	52		Ingestion	iii suicide	
210+	85	nifedipine Procainamide	Ingestion	Acc misuse	59 μg/ml
319‡ 320	86	Procainamide (10-fold error)	Parenteral	Acc misuse	59 μg/m
321	16	Propafenone	Ingestion	Int suicide	
322*	55	Propranolol	Ingestion	Int suicide	
323	70	Quinidine	Ingestion	Int suicide	
323	70 48	Verapamil	Ingestion	Int unknown	
324	40	atenolol	ingestion	iiit diikiiowii	
		ethanol			210 mg/dl
325	40	Verapamil	Ingestion	Int suicide	210 mg/ai
020	40	lithium	mgcstion	int suicide	1.3 mEq/L
326	51	Verapamil	Ingestion	Int suicide	1.1 mg/dl§
			•		9, 43
See also	cases 265, 28	7 (digoxin); 238 (metoprolol); 228 (pind	olol); 201 (propranolol,) .	
Cold and co	ough prepara	tions			
327	19	Triprolidine/pseudoephedrine	Ingestion	Unknown	
		aspirin			85 mg/dl, 8 h
		ethanol			
See also	case 170 (dex	tromethorphan).			
	*				
•	and minerals		Ingostica	Acc gon	02 000a/dl
328† Pastrointos	18 mo	Ferrous sulfate	Ingestion	Acc gen	23,000 µg/dl
329*	tinal preparat 67		Ingestion	Haknowa	
	67 40	Dicyclomine	Ingestion	Unknown	
330†	40	Loperamide salsalate	Ingestion	Int suicide	90 mg/dl
331†	16	saisaiate Sodium bicarbonate	Ingestion	Int micuse	an makai
0011			Ingestion	Int misuse	
ormonos s	and hormone	antagoniete			

Miscellaneous drugs

See also case 153 (methylene blue).

TABLE 15. Continued.

	Age		Route of		
Case	(yr)	Substances	Exposure	Reason	Blood Levels**
Sedative/h	ypnotic and a	antipsychotic agents.			
332*	69	Alprazolam	Ingestion	Int suicide	
333	>17	Butabarbital	Ingestion	Int suicide	30 μg/ml
		ethanol	3	, , , , , , , ,	- p- p- g- · · · ·
334	50	Chloral hydrate	Ingestion	Int suicide	
335	55	Chloral hydrate	Ingestion	Int suicide	
336	53	Chlorpromazine	Ingestion	Int suicide	
337	63	Chlorpromazine	Ingestion	Int suicide	
338*	35	Clonazepam chloral hydrate maprotiline	Ingestion	Int suicide	151 ng/ml
339*	>17	Ethchlorvynol diazepam	Ingestion	Int suicide	45 μg/ml
340	33	Ethchlorvynol glutethimide codeine	Ingestion	Int unknown	
341*	54	Ethinamate	Ingestion	Int suicide	
342*	18	Glutethimide acetaminophen/codeine	Ingestion	Int abuse	9 μg/ml§ 12 μg/ml§ [¶]
343*	32	Glutethimide acetaminophen/codeine	Ingestion	Int abuse	5.2 μg/ml 12 μg/ml [¶]
344†	31	Haloperidol	Parenteral	Adv rxn	0.1 μg/ml
345	75	Mesoridazine	Ingestion	Int suicide	, -
346*	87	Pentobarbital	Ingestion	Int suicide	30.8 µg/ml
347	18	Pentobarbital ethanol	Ingestion	Int suicide	27 μg/ml
348	35	Perphenazine desipramine chlorpromazine	Ingestion	Int suicide	
349	39	Phenobarbital	Ingestion	Int suicide	91 μg/ml, 12-15 l
350	37	Promethazine diflunisal	Ingestion	Int suicide	0.1 μg/ml§ 260 μg/ml§
351*	39	Temazepam	Ingestion	Int suicide	
352	59	Thioridazine	Ingestion	Int suicide	11 μg/L
353†‡	>17	Thioridazine	Ingestion	Adv rxn	• •
354‡	92	Thioridazine haloperidol	Ingestion	Adv rxn	
355	22	Thiothixene diphenhydramine	Ingestion	Int suicide	
356	58	Triazolam	Ingestion	Int suicide	
357*	20	Unknown barbiturate ethanol	Ingestion	Int suicide	
358	24	Sleep-aid/diphenhydramine opiate	Ingestion	Int suicide	
359*	31	Sleep-aid/diphenhydramine	Ingestion	Int suicide	

See also cases 191, 192, 224, 245, 262 (alprazolam); 246 (chloral hydrate); 247 (clorazepate); 156, 160, 171, 204, 248, 305, 382, 386 (diazepam); 288 (ethchlorvynol); 194, 264, 293 (flurazepam); 195, 383 (glutethimide); 196 (haloperidol); 233 (lorazepam); 403 (meprobamate); 251 (mesoridazine); 200, 210, 250 (perphenazine); 239 (phenobarbital); 125 (temazepam); 251 (thioridazine); 228 (thiothixene); 164, 205, 307 (triazolam); 309 (trifluoperazine); 125 (sleep-aid/diphenhydramine); 2 (unspecified benzodiazepine).

Stimulants	and street d	rugs			
360*	38	Amphetamines	Ingestion	int unknown	
361†	1	Caffeine (diet aid)	Ingestion	Acc gen	161 mg/dl, >40 hr
362	15	Caffeine <i>I-</i> thyroxine	Ingestion	Int suicide	
363†	19	Cocaine	Ingestion	Int misuse	
364	20	Cocaine	Inhalation	Int abuse	
365	20	Cocaine	Parenteral	Int abuse	
366*	23	Cocaine	Ingestion	Unknown	24 μg/ml§
367*	23	Cocaine	Unknown	int abuse	
368	25	Cocaine	Inhalation	int abuse	
369	26	Cocaine	Parenteral	Int unknown	
370*	27	Cocaine	Inhalation	Int abuse	
371*	28	Cocaine	Unknown	Int abuse	
372	29	Cocaine	Ingestion	Int suicide	0.015 μg/ml§#
373*	29	Cocaine	Parenteral	Int Abuse	
374	30	Cocaine	Unknown	Int abuse	
375*	31	Cocaine	Parenteral	Int abuse	

TABLE 15. Continued

_	Age		Route of	_	.
ase	(yr)	Substances	Exposure	Reason	Blood Levels*
376*	35	Cocaine	Unknown	Unknown	
377*	36	Cocaine	Inhalation	Int abuse	
378*	49	Cocaine	Parenteral	Int abuse	16 μg/ml§
379*	50	Cocaine	Inhalation	Int abuse	15
380*	58	Cocaine	Parenteral	Int abuse	6.2 μg/ml§
381*	28	Cocaine	Parenteral	Int abuse	υ.= μ.gg
		amphetamine	, a		
382*	33	Cocaine	lng + paren	Int abuse	2.4 μg/ml§#
		propoxyphene	g / paren	45 450	9.8 μg/ml§
		p. 0 p 0 x , p		Norpropoxyphene	20.8 μg/ml§
		diazepam		Nordiazepam	0.3 μg/ml§
383	36	Cocaine	Ing + paren	Int unknown	ο.ο μασς
000	. 00	glutethimide	mg / paren	int unknown	13.4 mg/dl
		acetaminophen/codeine			85 μg/ml¶
384	54	Cocaine	Parenteral	Int abuse	ου μισ/ππ
JU4	5 4	heroin	raiemerai	mit abuse	
385*	27	Heroin	Parenteral	Int abuse	
386†	25	Heroin	Ing + inhal	Int abuse	
300 (23		•	int abuse	
		cocaine	+ parenteral		
387*	29	diazepam Heroin	Paren + ing	Int abuse	160 na/mls#
307	29	cocaine	Faren + ing	int abuse	160 ng/ml§#
		ethanol			71 m a/di
388*	26	Heroin	Daron Lina	let obves	71 mg/dl
300	20		Paren + ing	Int abuse	
		ethanol			
000*	07	cocaine	D		400 - / -10 //
389*	27	Heroin	Paren + ing	Int abuse	160 ng/ml§#
		ethanol			100 mg/dl§
000+	0.4	marijuana	Б.		98 ng/ml§#
390*	31	Heroin	Paren + ing	Int abuse	
0044		ethanol			
391*	46	Heroin	Parenteral	Int abuse	870 ng/mi§#
		methamphetamine			
		codeine			
392	26	Methamphetamine	Unknown	Int unknown	
393*	47	Methamphetamine	Unknown	Int unknown	4.7 μg/ml§#
394	29	Methamphetamine	Ingestion	Int abuse	
		diphenhydramine			
395*	26	Methylphenidate	Parenteral	Int unknown	
396	38	Methylphenidate	Ingestion	Unknown	
397*	27	Phencyclidine	Unknown	Int abuse	
398	30	Phencyclidine	Ingestion	Int suicide	0.4 μg/ml§
399	21	Phencyclidine	Ingestion	Int abuse	
		cocaine			
400	29	Phencyclidine	Ingestion	Int unknown	
		cocaine			
401	33	Phencyclidine	Ingestion	Int abuse	
		cocaine			
402	25	Phencyclidine	Ingestion	Unk reason	
		rodenticide (unknown type)	-		
403*	29	Phenmetrazine	Parenteral	Int abuse	
		meprobamate			

See also cases 174, 225, 314 (amphetamines); 170 (cocaine); 153 (isobutyl nitrite, Rush); 289 (phenylpropanolamine); 165 (unspecified sympathomimetic).

Topicals					
404*	4 mo	Merthiolate (?aspiration)	Ingestion	Unknown	
405†	52	Povidone iodine antiseptic	Other	Acc misuse	
406	20	Camphorated oil	Ingestion	Unknown	5 μg/ml§

^{*} Prehospital cardiac arrest

[†] Abstract of case provided at conclusion of manuscript.

[‡] Chronic exposure; all others are acute

[§] Level obtained postmortem

[¶] Acetaminophen level

[#] Level includes metabolite and parent compound

^{**} Where multiple blood levels were available, the highest level obtained is reported. Time after exposure is unknown unless indicated.

TABLE 16. Demographic Profile of Exposure Cases by Generic Category of Substances and Products; Nonpharmaceuticals*

						Reason		Treated		Č			
	of		Age (years)				Adv	i		- 1	Outcome		
	Exposures	9>	6–17	>17	Acc	Int	Rxn	HGF	None	Minor	Moderate	Major	Death
Adhesives/glues	11,747	6,642	1,490	3,336	11,581	118	+	2,120	4,757	3,577	238	6	-
Alconois Ethanoit	17,608	4,088	1,910	11,116	6,921	10,104	177	11,106	3,829	5,933	1,709	288	19
Isopropanolt	4,245	3,005	278	912	3,920	285	7	956	2,267	656	89	14	0
Methanol	975	370	102	480	888	61	4	200	435	309	27	77	9
Rubbing alcohol													
Ethanol	1,561	1,239	85	226	1,489	48	က	228	974	249		7	0
Isopropanol	5,798	4,546	309	880	5,415	362	0	1,102	3,092	1,041	66	15	-
Unknown type	249	187	18	40	231	18	0	64	133	51	4	-	0
Other/unknown	606	351	102	445	601	276	12	438	299	271	63	ω	0
TOTAL	31,345	13,786	2,801	14,099	19,475	11,154	203	14,364	11,029	8,813	2,002	339	56
Arts/crafts/office supplies Auto/aircraft/boat products	18,809	15,060	2,367	1,204	18,542	192	ω	875	10,341	1,334	62	9	4
Glycols	1.822	556	148	1.080	1.739	72	-	672	742	564	22	2	4
Hydrocarbons	866	909	78	295	992	22	0	184	460	353	18	7	0
Methanol	202	345	57	293	655	47	Υ-	375	377	166	25	6	5
Other/unknown	666	449	105	425	979	16	-	316	329	447	41	5	0
TOTAL	4,525	1,958	388	2,093	4,365	140	က	1,547	1,908	1,530	141	37	თ
Batteries													
Peniight/flashiight/dry			0	ļ	1	3	c		Č	203	Ö	•	c
Cells	1,794	1,283	328	1/1	0//,	7 '	> \	45.	0 C	280	0 6		o 0
Automotive	1,215	211	138	837	1,203	ກຸ	- (415	G 77.2	240	9 4	4 -	> 0
Button batteries	1,221	893	166	149	1,202	17	o ·		86/	011	4.	4 (> (
Other/unknown	257	155	47	51	253	_	_	20	114	ภ	4 ;	-	> '
TOTAL	4,487	2,542	629	1,208	4,428	48	7	1,460	1,956	1,440	145	တ	0
Bites and envenomations													
Fish and coelenterate	1,076	64	238	750	1,058	က	<u>გ</u>	369	51	662	159	N	0
Insects											,	i	
Bee/wasp/hornet	11,597	2,960	2,602	5,861	11,380	0	174	2,099	759	7,953	529	54	0
Scorpion	2,966	273	510	2,136	2,958	Ψ-	က	419	164	2,230	189	16	0
Other	3,302	1,169	635	1,433	3,247	0	40	757	410	1,862	153	ഹ	0
Mammals	2,598	675	848	1,006	2,568	80	12	1,175	474	1,237	159	α	0
Reptile—other/unknown	195	09	79	51	195	0	0	39	40	83	7	0	0
Snakes—exotic	199	21	39	136	194	0	~~	163	16	94	44	∞	0
Snakes indigenous to U.S.													
Rattlesnake	303	19	47	225	301		0	273	53	82	95	37	0
Copperhead	44	9	=	24	43	0	0	4	2	19	14	0	0
Coral	19	S	သ	6	18	0	0	. 15	8	7	-	0	0
Cottonmouth	37	2	80	56	37	0	0	34	က	18	ω	-	0
Nonpoisonous snake	611	84	323	196	601	-	4	129	153	335	4	0	0
Unknown crotalid	9	τ-	2	က	9	0	0	S	2	-	ო	0	0
Unknown type of snake	1,002	101	351	526	995	0	4	496	223	482	20	-	0

	1,537 219 199 538 60 62 10,729 2,447 1,787			1,532 534 10,625	N O N	0 3 79	487 381 2,439	293 33 671	750 194 6,492	209 135 713	12 7	0 - 0
8,166 7		20.	20,173	36,292	21	333	9,321	3,325	22,508	2,464	127	-
4,316 2,404 286		***	1,530	4,269	12	5	965	1,705	1,154	219	ω	0
1,550 992 123			411	1,499	40	-	301	583	446	24	4	0
58			732	833	ည	0	645	82	391	208	18	8
756 5		m	3,519	4,863	91	4	2,372	901	2,611	456	24	
_	_	Ψ,	,601	3,130	47	က	1,236	832	1,292	285	34 9	- (
1,782 548 178	_	-	200,	1,720	2	_	986 4	985	COA	8	٥	>
2.335 1.548 164			599	2.226	89	ო	475	1.280	. 265	19	4	0
86 35 12	<u>.</u> .		33	84	0	-	X	15	ဗ္ဗ	ო	-	0
512 32 23			437	424	47	23	300	124	132	52	=	10
2	-		13	18	0	0	œ	7	-	က	7	0
1,150 284 154			665	1,089	43	7	483	785	480	53	22	0
2.228 1.198 158			837	2,150	53	ç	592	806	615	54	19	4
			561	1,063	9	7	458	296	471	9	-	0
									· ·.			
1,404 368 153			836	1,365	25	4	559	295	745	93	4	8
721 265 164			276	989	33	લ	239	276	225	8	4	_
		•	5	7	Ţ	٢	900		Ċ		•	•
701 044 017,1		-	÷20,-	60.	2	•	060	ç,	800 0	6	†	>
66 10 7			46	59	31	-	20	15	15	2	က	_
	,			382	4	ღ	226	41	210	20	0	0
		4		9,604	187	39	2,875	3,340	2,929	350	5 8	0
33,945 12,933 3,146	_	16	6,973	32,856	772	107	12,032	10,032	12,665	1,937	170	22
4 458 2 070 330		_	1 968	4.310	123	œ	1 068	1 382	1 844	171	5	•
o Î		•	2		<u>}</u>	•	9	300,	<u>.</u>	:	1	-
18,000 9,405 1,290	_	9	6,962	17,495	391	23	3,873	5,969	7,346	460	5 4	0
,	_		5	2	=	t	200	460	- 20	<u>0</u>		>
6,026 5,107 235 1,199 940 53			632 193	5,919 1,181	89 14	4	457 152	3,188 624	1,137 246	49 15	- 5	00

ABLE 16. Continued

	Number	•				Reason	!	Treated		ć			
	of	4	Age (years)) Adv	ij	-	ino	Оптсот		
	Exposures	9>	6-17	>17	Acc	Int	Rxn	HCF	None	Minor	Moderate	Major	Death
Disinfectants (household)													
Hypochlorite-containing	3,356	1,390	348	1,574	3,295	49	9	798	869	1,526	144	∞	0
Phenol	1,705	1,086	121	472	1,592	100	0	364	754	492	28		0
Pine oil	5,102	4,123	221	902	4,926	147	က	1,152	2,792	1,194	26	9	0
Other/unknown	298	367	43	178	574	20	-	147	261	194	16		0
Drain Cleaners													
Acid	180	58	13	137	178	0	0	98	21	102	22	 -	0
Alkali	255	78	24	144	243	Ξ	0	113	54	121	28	8	8
Other/unknown	40	89	4	23	37	8	0	16	10	. 16	7	0	0
Electric dishwasher													
detergent													
Alkali	3,801	3,418	72	283	3,783	80	7	250	2,434	647	21	8	0
Other/unknown	1,095	958	31	103	1,094	0	0	73	602	192	വ	0	0
Fabric softeners													
Cationic	1,022	945	22	25	1,011	က	က	45	617	117	-	0	0
Other/unknown	74	64	0	10	73	0	0	വ	47	10	-	0	0
Glass cleaners													
(household)	4,720	3,894	288	504	4,631	78	-	320	2,543	096	22	01	0
Hand dishwashing	r G	1	1	,	0	ć	¢	Š	100		ć	•	c
detergents Industrial cleaners	6,598	2,0,7	3/1	7,092	6,527	ê,	٥	087	2,783	1,945	P)	_	>
Acide	103	17	17	153	190	ď	c	137	27	114	δ	4	c
2003	5 ag	- 67	- 8	450	674	α	o c	595	136	365	3 2	rα	· C
Alkail	000	- 6	9 6	t 1	1 0	ļ) 1	3 6	2 5	3 6	7 1	o (> 1
Other/unknown	/08	24/	?	4/0	88/	<u>`</u>	-	300	218	365	22	7	-
Laundry detergents					1	!	,	!		,		,	,
Anionic/nonionic	5,808	4,786	211	763	5,725	45	50	493	2,708	1,736	22	က	0
Alkali	2,714	2,398	70	234	2,685	19	4	394	1,332	815	9		0
Other/unknown	068	723	35	126	873	æ	2	97	418	263	11	0	0
Miscellaneous													
Acid	423	145	40	226	414	6	0	171	125	179	45	-	-
Alkali	5,873	2,619	449	2,652	5,678	172	9	2,151	1,798	2,414	397	46	0
Anionic/nonionic	5,905	4,273	295	1,267	5,775	96	7	744	2,565	1,518	63	8	0
Cationic	2,418	1,465	190	717	2,343	29	7	266	1,047	749	99	9	7
Methanol/qlycols	1,621	1,262	100	246	1,591	25	-	179	776	496	16	-	0
Isopropanol	1,141	876	63	194	1,076	09	-	202	277	220	15	4	0
Ethanol	83	70	S	7	80	က	0	14	41	2	ო	0	0
Other/unknown	1.892	1.281	123	444	1,847	37	2	424	835	470	44	-	0
Oven cleaners	į.												
Alkali	2,488	887	219	1,290	2,456	24	-	945	474	1,359	216	Ξ	0
Other/unknown	161	47	13	86	154	9	0	69	27	72	17	-	0
Bust removers													
Hydrofluoric acid	555	86	53	450	540	13	0	406	98	287	93	4	0
)))	ì	!	F .		ı				!		

00	-0	90	000	0 4		0 0	00	o c	0	0	0 0	- -	,	c	, ,	- c	0	0	0	2		0	0	o c	> 0	> C	o c	0
ю N	- 0	24	400	182	0	00	0 0	0 0	0	9	0 (n 0	טו	c		ဖင	0	2	0	56		0	ကျ	4 K	o 0	> C	ه د	ı
76 10	12	113	85 15 7	47 2,746	m	12 E	788	4 -	- 0	140	ام ج	£ 2	30	S	}	92 12	5 4	36	10	453		13	~ 5	<u>2</u> &	9 5	<u>.</u> 2	24	27
559	140	840 241	941 239	93,726	446	582	791	129 18	2 09	2,929	117	540 1.195	1,117	960	3 ;	2,741	260	1,414	310	13,900		433	29	955 805 805	620	752	482	531
295 55	184 194	823 937	564 503	950 950 43,491	1 649	4,056	2,910	90 92 92 93	417	5,557	1,031	1,701	3,554	204	3	13,037	1.159	3,102	537	43,366		2,041	935	7.040	20,1	1,532 273	3.353	294
365 46	98	607	569 125 62	386 19,581	60	321	261	% %	3 8	1,121	25	346	771	164		1,16/	181	432	80	5,785		212	9 4	587	5 6	310	350	341
00	- -	4 0	φ - -	135	7	21	9 (9 (- ო	27	ကဖ	ထက	· -	0	1 (<u>ა</u> ლ	<u>ა</u> ო	<i>L</i> 9) 21	245		ഹ	o ,	- ‹‹	ָּיָּ כ	<u> </u>	- ^	0
3 3	12	64 9	28 16	40 1,880	4	65 90	57	16 0	1 m	159	- 3		141	₩.	- (165	- 5	55	2	952		18	(ຄແ	1 6	· .	34	53
1,089	401 324	2,058 1,581	1,965	2,041 102,154	9.019	6,980	5,497	288 148	748	11,659	1,868	2,897 5,242	5,857	4 0.48		21,033	6/3 2.245	6,435	1,138	78,745		3,368	1,337	7,532	001	7,590	1,307 5,827	1,047
686 103	133 13	865 211	827 193	578 578 28,803	76	652	388	45 8	47	1,478	4 1	471 165	200	170	1 (- !	732	93	616	83	6,574		184	17	30£	C	109	66 8 80 8	661
77	19	126 55	109 54	97 97 6,101	92	224	228	5 5	25	710	55	549 196	334	4	2	203	ව දි	271	09	3,576		149	ω (36	6 C	07.1 07.8	452	243
324 44	259	1,110	1,015	1,386 68,070	2,873	6,170	4,934	170	674	609'6	1,770	2,075 4 896	5,136	CCO	3	19,962	520 2.110	5,636	1,007	69,525		3,051	1,311	2,244 6,606	0,000	2,318 1.158	4.460	132
1,110	416 326	2,133 1,595	2,005	5/8 2,090 104,546	3 030	7,094	5,581	312	756	11,917	1,876	3,121	6,015	4	200	21,268	903 2.274	6,576	1,160	80,214		3,402	1,339	7,552	62,7	2,618	1,000 F 883	1,081
Other acid Other/unknown	Spot remover/dry cleaning agents Starch	Acid Other/unknown	Wal/floor/tile cleaners Alkali Anionic/nonionic	Giycols Other/unknown Total	Cosmetics/personal care products	Creams, lotions, make-up	Deodorants	Depilatories	Eve products	Hair care products	Lipsticks and lip balms	Mouthwash	Nail polish removers	Nail products,	Perfume/ cologne/	aftershave	Peroxide	Soaps (bar, hand, complexion)	Suntan/sunscreen products	TOTAL	Deodorizers (not for personal use)	Air Fresheners	Diaper pail deodorizers	Other	IOIAL	Dyes Encontint oils	Essential olls	Fire extinguishers

TABLE 16. Continued

	Number					Reason	1	Tenton			;		
	jo		Age (years)				754	in		ō	Outcome		
	Exposures	9>	6-17	>17	Acc	Int	Rxn	HCF	None	Minor	Moderate	Major	Death
Food products/food poisoning Foreign bodies/toys/	38,691	9,207	4,934	23,333	32,500	170	5,767	4,366	9,836	12,554	1,011	17	0
miscellaneous Bubble blowing solutions	1.849	1.746	92	19	1.841	C	0	43	839	505	ო	0	c
Christmas ornaments	1,089	1,027	2 88	2 5	1,089	0	0	5 45	594	9/	, ,	0	0
Coins	2,585	2,168	332	72	2,572	10	0	749	1,204	289	6	_	0
Dessicants	10,290	9,341	619	250	10,232	25	0	434	5,614	154	2	0	0
Feces/urine	1,161	1,030	44	82	1,140	41	8	92	569	73	2	0	0
Glass	881	430	65	366	698	2	7	142	388	129	16	0	0
Soil	1,462	1,327	24	102	1,459	0	0	104	99/	125	19	-	0
Thermometer	7,433	4,392	1,933	926	7,385	53	2	384	3,948	197	4	0	0
Toys	2,903	2,492	329	64	2,885	7	4	140	1,736	167	9	0	0
Other/unknown foreign													
pody	11,868	8,478	1,233	2,024	11,711	69	22	1,970	5,575	1,602	311	52	0
TOTAL	41,521	32,431	4,693	3,976	41,183	159	37	4,085	21,233	3,317	373	27	0
Fumes/gases/vapors													
Carbon monoxide	4,287	514	552	3,093	4,068	157	8	2,404	462	2,337	429	53	19
Chloramine	1,299	37	49	1,167	1,271	58	0	394	88	817	104	-	0
Chlorine gas (mixing													
household products)	673	34	34	629	099	12	0	526	44	470	80	က	0
Chlorine gas (other)	3,174	429	589	2,096	3,151	15	7	1,231	363	1,899	311	14	0
Hydrogen sutfide	439	40	25	346	434	-	0	172	29	212	37	2	7
Methane	941	144	102	649	894	41	0	436	163	464	22	S.	-
Polymer fume fever	20	က	4	13	20	0	0	τυ	7	8	က	0	0
Propane/simple													
asphyxiants	547	28	130	340	478	64	0	219	109	267	43	_	0
Other/unknown	2,469	298	217	1,827	2,423	53	80	1,041	462	1,127	173	12	-
TOTAL	13,849	1,557	1,702	10,110	13,399	347	12	6,158	1,765	7,601	1,237	91	23
Fungicides (non-medicinal) Heavy metals	1,203	522	142	510	1,188	10	7	529	477	337	33	-	-
Arsenic	399	109	27	248	360	52	2	208	112	87	21	7	0
Copper	583	142	148	255	564	15	m	207	176	234	55	0	
Lead	1.181	647	162	350	1,153	21	-	391	506	120	33	4	_
Mercury	1.121	368	225	440	1,081	56	9	284	573	155	13	9	0
Metal fume fever	836	99	24	724	828	က	- -	254	70	471	106	7	0
Selenium	45	16	m	21	34	G	4	13	17	10	2	0	0
Thallium	<u>.</u>	9	0	· •	=	0	0	_	2	2	-	· 	0
Other/unknown	1.000	390	83	489	975	12	4	357	337	263	47	9	0
TOTAL	5,178	1,744	829	2,533	5,006	110	21	1,721	1,796	1,342	243	56	8
Herbicides													
2,4-D or 2,4,5-T	1,450	541	145	742	1,428	14	7	410	490	426	55	ß	-
Diquat/paraquat	224	78	19	168	208	11	7	118	24	71	9		ო

0 4	000	40+	00-	0 0	- 0	0 - 10	4 0	0 00	000%0	0 000	00
4 0	- 0 5	ဖထထ	ဝက်ဆ	2 27 99	N C	54 6	62	- 80	6 4 0 15 128	4 -0-	0 0
95 156	9 32 284	100 130 65	25 90 90	118 27 323 1,222	4 α	105 88 2	309	50 50 50	109 62 120 926	84 2 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	17 0
705 1,202	36 623 6,348	1,271 935 589	374 159 1,301	1,104 499 3,335 16,574	. 18	761 829 14	2,548	142 178 45	891 581 807 1,177	1,690 65 83	162 44
667	32 481 4,366	866 1,211 1,052	1,572 810 1,881	540 5,615 19,177	98	2,387 1,751 161	3,082	218 237 45	969 559 1,119 3,366	285 1,270 352 1,622	1,281
705 1,233	46 400 2,416	980	297 233 947	900 408 2,798 11,000	57 465	896 976 50	2,650	125 165 35	651 434 230 1,381 8,633	492 74 69 143	335 33
16 20	00-	e − 0	00-0	2 2 2 2 2	de des	- ထက္က ဝ	34	0	36 22 7 14 168	9 0	00
16	5 40 397	90 25 78	41 71 88	147 83 220 1,184	8 9	္တင္ဟ မွ	135	25 12	38 42 13 121 701		e ⊢
2,171 3,807	92 1,453 12,818	2,979 2,733 1,999	2,369 1,181 2,910	2,344 1,325 11,387 44,590	140	4,331 3,606 251	8,373	497 596 144	2,725 1,661 2,401 6,128 35,489	2,353 2,086 626 2,712	1,791
1,271 2,181	61 672 5,849	2,379 448 347	290 74 1,035	1,236 413 3,310 16,114	30	1,205 1,228 30	4,620	267 275 63	1,073 815 211 1,873 13,087	721 34 37 71	134 43
227 391	8 210 2,745	222 133 118	116 26 272	256 144 763 5,013	90 50	209 357 10	189	46 42 41	304 155 357 445 2,908	733 32 71 103	68 13
629	29 509 4,527	328 2,160 1,597	1,958 1,090 2,639	945 840 7,390 24,012	113	2,932 2,932 2,059 211	3,027	190 283 68	1,356 723 1,850 3,759 19,629	868 2,030 519 2,549	1,598
2,209	100 1,494 13,271	3,097 2,771 2,081	2,386 1,200 3,998	2,510 1,421 11,676 46,005	149	4,423 3,743 257	8,583	527 612 146	2,809 1,737 2,439 6,286 36,541	2,403 2,103 635 2,738	1,811
Other/unknown Total	Hydrocarbons Benzene Diesel fuel Gasoline	Halogenated hydrocarbons Kerosene Lighter fluid/naphtha	Lubricating/motor oils Mineral seal oil Mineral spirits/varsol	l oluene/xylene Turpentine Other/unknown Total.	Insecticides/pesticides (excluding rodenticides) Arsenic-pesticides only Borates/boric acid	Carbamates Chlorinated hydrocarbon Metaldehyde	Organophosphate alone Organophosphate and carbamate Organophosphate and	hydrocarbon Organophosphate and other pesticide Piperonyl butoxide alone	Piperonyl butoxide and pyrethrins Pyrethrins alone Insect repellants Other/unknown	Lacrimators Matches/fireworks/ explosives Matches Other/unknown ToraL	Moth repellents Napthalene Paradichlorobenzene

TABLE 16. Continued

	N ada					Reason	ļ	Treated		č	0 4 1		
	of		Age (years)				Adv	. <u>⊆</u>		5	Icome		
	Exposures	9>	6–17	>17	Acc	ıut	Rxn	HCF	None	Minor	Moderate	Major	Death
Other/unknown	1,672	1,480	87	95	1,660	6	-	266	1,143	112	-	0	0
TOTAL	3,926	3,461	168	569	3,892	13	-	634	2,706	318	18	2	0
Mushrooms	8,330	6,885	482	879	7,868	365	51	1,744	5,910	948	215	55	0
Paints and stripping agents	13,610	8,588	965	3,827	13,353	181	21	2,142	6,008	3,130	269	50	Ø
Photographic products	842	602	22	171	835	4	0	112	441	125	13	0	0
Plants								•			Ċ	•	c
Anticholinergic	457	237	113	102	326	122	-	192	509	108	25	4	Э
Cardiac glycosides	2,097	1,627	252	200	2,051	35	4	352	1,356	163	24	4	0
Colchicine	18	15	-	2	18	0	0	-	12	_	0	0	0
Cvanogenic glycosides	2,924	2,373	328	193	2,883	14	16	202	1,731	137	12	4	0
Depressants	372	349	14	80	369	-	0	26	283	17	0	0	0
Dermatitis	10,082	6,782	066	2,148	9,882	44	106	911	4,134	2,679	301	9	-
Gastrointestinal irritants	15,121	13,075	894	1,024	14,920	109	41	666	9,205	1,530	111	വ	0
Hallucinogenic	295	213	42	37	265	28	-	54	178	27	4	-	0
Nicotine (no tobacco													
products)	236	164	36	33	221	7	7	62	109	20	ო	0	0
Nontoxic plant	24,491	22,438	926	968	24,293	70	20	650	12,766	1,006	09	4	0
Oxalate	15,327	14,233	478	520	15,232	99	4	267	9,653	2,155	78	7	0
Solanine	2,167	1,874	143	130	2,143	ი	12	272	1,537	195	24	တ	0
Stimulants	316	263	25	25	313	2	0	99	203	35	വ	0	0
Toxalbumins	289	201	37	48	273	=	0	123	162	98	21	0	0
Other/unknown	10,217	8,670	892	555	10,015	94	48	886	6,187	971	91	თ	-
TOTAL	84,409	72,514	5,171	5,921	83,204	602	230	5,363	47,725	9,142	786	48	7
Polishes and waxes	1,795	1,458	73	252	1,761	58	2	187	1,007	397	16	-	0
Radio-isotopes	126	15	16	06	123	2	0	47	23	28	വ	0	-
Rodenticides									,	,	;	•	,
Anticoagulants	7,723	6,972	178	481	7,490	199	ო	1,911	4,934	222	. 29 29	-	- ·
Strychnine	103	39	თ	49	78	18	0	54	44	13	ო	-	N
Other/unknown	879	682	38	136	825	48	0	338	532	63	10	က	-
TOTAL	8,705	7,693	225	999	8,393	265	က	2,303	5,510	298	42	Ŋ	4
Sporting equipment	672	424	151	84	652	18	0	185	357	114	23	2	0
Swimming pool/aquarium				;		!	•		ć	•	8	,	c
products	1,719	1,188	167	354	1,701	12	N	237	808	446	S i	- !	o (
Tobacco products	7,385	6,882	202	268	7,269	88	=	1,223	4,073	1,585	71	2	-
Spring House	A 20 A	4 437	1 425	2 734	8 496	165	52	1 938	3.466	2.316	199	24	0
200	500				5								

Abbreviations: acc, accidental; adv rxn, adverse reaction; int, intentional.

* Medical outcome data were also collected in categories labeled "unknown, nontoxic," "unknown, potentially toxic," and "unrelated effect." Thus, the numbers listed here do not represent the total poison exposure experience. Patients with totally unknown age, reason or medical outcome were omitted from the respective tabulations. † Excluding rubbing alcohol.

TABLE 17. Demographic Profile of Exposure Cases by Generic Category of Substance, Pharmaceuticals

	, and will		Age (years)			Reason		Treated		Š	9		
	of Exposures	9 >	6-17	>17	Acc	<u>t</u>	Adv Rxn	in HCF	None	Minor	Moderate	Major	Death
Analgesics													
Acetaminophen only	0	7		, ,	240	302 3	730	0 201	6.257	2 308	570	0	13
Adult formulation	13,834	4,208	4,00, +	0,510	0,749 31 644	0,730	<u> </u>	3,892	21.955	1.098	48	5 5	0
Pediatric formulation	01,970	30,013		790	0,10	1 1 1 1 0	3 8	1 534	1 457	499	146	35	0
Unknown type	3,3/8	00/,	- CO	206	7,140	601,1	25	t,00,1	, , , , , , , , , , , , , , , , , , ,	ř	2	3	ı
Acetaminophen			-										
combination with:	140.4	700	070	103	303	677	ŭ	7.42	464	361	7.	4	C
Aspirin	1,2/1	284	5/3	- 60 - 60 - 60 - 60 - 60 - 60 - 60 - 60	220	074	. i	7#/	7	100	990	۲ و	> <
Codeine	5,147	1,070	821	3,118	2,085	2,709	750	3,352	1,322	CD/,1	007	5 4	1 (
Oxycodone	1,225	189	160	842	476	646	77	786	566	3/3	> 1	9 :	N I
Propoxyphene	2,246	409	281	1,513	781	1,353	64	1,646	558	737	170	4	7
Other narcotic/analog	885	118	114	613	334	455	65	575	179	. 274	53	თ	•
Other drug	2.523	200	511	1,250	1,134	1,284	59	1,555	923	735	130	22	0
Aspirin only				•		•							
Adult formulation	6.317	1 983	1815	2.356	3 027	3.096	78	3.681	2.349	1.479	355	48	တ
Dodiotrio formulation	0000	2,000) , -	23.5	900 C	5.4	ο α	399	1.576	165	19	2	0
Fediatric Iorinulation	2,290	7,-13	† ;	- 0	2,220	7 00	င်	2000	20,0	390	8 0 0 0	1 4	5
Unknown type	5,659	1,785	1,564	2,162	2,699	2,788	28	4,334	7,040	080,1	200	1	<u>y</u>
Aspirin in combination													
with:													•
Codeine	1,049	186	149	692	397	287	4	722	216	361	78	17	-
Oxycodone	269	144	64	468	293	360	31	441	163	215	4	=	۲
Propoxyphene	94	13	10	89	32	53	ო	70	24	32	7	4	-
Other parcotic/analog	400	84	46	259	156	203	32	256	100	121	52	ო	-
Ourel Halcouc/allaiog	7 7	ָ מַ	ę ć	7 7	7	001	1 5	900	1 065	1050	173	00	-
Other drug	3,173	833	900	0.14,1	5,4	660,1	60	060,1	200,-	000,	2	1	-
Narcotics						:	;		. (ţ	(,
Codeine	998	310	102	428	459	333	29	452	251	257	42	2	_
Meperidine	417	51	48	306	145	229	္က	307	99	136	33	4	0
Methadone	165	22	16	125	22	94	=	115	24	35	19	თ	က
Morphine	130	28	ω	91	29	48	=	91	30	23	-	9	7
Pentazocine	317	31	32	236	95	180	38	201	33	129	35	∞	-
Propovvnhene	785	125	86	537	270	477	22	277	171	234	72	19	9
Simulation of the control of the con	500	101	2	330	937	238	37	336	102	151	49	24	4
Offier/unikriown	220	171	3 5	7 00	2 6	9 5	7	7 20	24.5	- C	9 6	, r	
Nonaspirin salicylates	026	282	2/	201	1/5	27	/ 1	181	243	2	22	ס	-
Nonsteroidal anti-													
inflammatory											•	;	,
fbuprofen	11,205	5,899	1,628	3,512	7,221	3,665	186	4,432	5,641	1,800	233	ဓ	-
Other/unknown	4,867	1,757	292	2,239	2,712	1,788	276	2,339	1,954	1,086	186	23	7
Other/unknown	730	483	64	161	. 295	143	19	280	372	137	33	9	0
TOTAL	102.759	55,629	15,527	29,969	68,304	31,345	1,876	42,619	49,807	17,001	3,336	586	85
!	0000			002	000	•		203	1 067	673	27		_
Anesthetics	3,289	2,466	239	939	3,086	132	747	287	,00,	2/6	ò 6	- G	> +
Anticholinergic	3,667	1,314	511	/9/,۲	9/6'L	۲,501 ر	128	2,220	- 5,-	000,-	- L	S ,	- <
Anticoagulants	440	271	30	126	338	98	13	188	1/8	53	cl cl	Ω.	>

TABLE 17. Continued

	1		Age (years)			Reason		Trooted		(
	of						Adv	in		5 O	Outcome		
	Exposures	9 >	6-17	>17	Acc	nt	Bxn	HCF	None	Minor	Moderate	Major	Death
Anticonvulsants	i									,	,	į	
Carbamazepine	1,516	540	274	681	940	206	53	096	481	461	190	21	4
Phenytoin	2,595	728	331	1,467	1,460	1,011	72	1,782	801	754	297	4	-
Valproic acid	402	203	61	130	315	9/	8	175	207	85	19	ო	0
Other/unknown	103	45	21	36	. 78	24	0	48	45	56	9	~	0
TOTAL	4,616	1,516	687	2,314	2,793	1,617	133	2,965	1,531	1,323	512	96	ഗ
Antidepressants													
Cyclic antidepressants									!	,	ļ		;
Amitriptyline	3,400	456	342	2,503	1,048	2,203	20	2,896	545	938	693	349	52
Amoxapine	329	47	50	287	97	244	1	310	51	115	75	53	ည
Desipramine	717	141	80	475	245	430	24	969	168	222	6	4	2
Doxepin	1,918	155	163	1,555	514	1,315	39	1,654	254	209	353	161	Ξ
Imipramine	1,954	430	319	1,162	780	1,087	52	1,537	200	614	276	97	13
Maprotiline	356	46	58	280	106	237	9	299	69	105	22	56	-
Nortriptyline	458	33	22	358	112	326	Ξ	384	88	133	92	31	က
Protriptyline	63	80	2	48	14	45	2	49	16	22	ო	0	0
Formulated with a:													
Benzodiazepine	433	61	6E	324	113	294	9	371	72	144	70	35	0
Phenothiazine	870	175	96	574	287	547	13	745	188	285	138	99	ß
Other/unknown	989	11	51	238	220	417	58	555	105	203	120	40	ა
Lithium	1,509	157	138	1,147	551	830	81	1.215	353	485	177	61	4
MAO inhibitor	528	64	14	432	180	255	84	409	120	154	101	16	9
Trazodone	1,129	136	107	857	374	089	51	867	253	436	96	15	-
Other/unknown	46	7	เก	90	12	30	8	35	80	80	9	ო	0
TOTAL	14,428	1,999	1,464	10,570	4,653	8,940	460	11,922	2,790	4,471	2,331	296	100
Antihistamines													
H, blockers	1,285	515	181	268	783	434	25	627	611	230	45	თ	_
Diphenhydramine	7,175	3,512	1,016	2,518	4,509	2,412	146	3,421	2,800	2,029	363	43	9
Other/unknown	3,263	1,538	657	1,009	2,227	916	81	1,364	1,500	787	112	28	0
TOTAL	11,723	5,565	1,854	4,095	7,519	3,762	279	5,412	4,911	3,046	517	20	7
Antimicrobials													
Antibiotics	24,260	16,277	2,946	4,728	19,157	3,376	1,556	4,946	11,786	3,177	305	8	-
Antifungals	2,921	2,297	134	450	2,816	99	30	175	1,516	383	4	4	0
Antihelmintics					!	,					•		•
Diethylcarbamazine	2,631	1,645	97	862	2,586	23	_	124	1,592	127	က	_	0
Other/unknown	704	222	61	79	688	တ	9	8	416	72	က	0	0
Antiparasitics	•	!	:	• •	í		!	(į	ć	•	•	,
Antimalarials	114	42	18	49	78	55	12	62	/e	35	: œ	· O	- (
Metronidazole	240	150	63	309	303	148	83	193	174	147	21		-
Other/unknown	673	440	83	160	544	29	24	126	354	101	œ	-	0
Antituberculars		(ţ	(ř	ć	,	1	ï	Ċ	ć	ć	ć
Isoniazid	189	89 ! 87	45	86 ! 85	4 (χ Υ	21	86 L	4 i	S ;	ج م	۹ ۹	> (
Other/unknown	42	17	œ	17	83	9	13	202	1		Ω	N	>

	0 0						1 0 87 21		15 10												> ,		0 0		2	7 0	56	76 1	2 0	22 0		2 0		1 0	16 1	3 0	0 0		1 0	0 0	25 1	10 0		
7	ω	411	4		495	99	გყ	3	8	225	182	23	86	9/	-	999				7	2		က		34	69	684	906	4	113		5		19	113	ო	13	17	41	2	213	98))	
45	16	4,147	49		1,282	009	7 58	5.	5	576	601	226	198	403	13	2,148				1,000	067,1		8		271	781	10 588	12,966	40	747		154		654	601	35	9/	234	202	=	1,964	1,557		
120	84	16,114	109		1,569	1,067	103	60 1,1	344	953	1.824	655	899	1,907	. 43	6,394				705	2,763		37		652	2,160	23 174	28,808	103	1,823		1,996		1,911	1,246	48	351	629	283	58	6,522	4,412	! : :	
84	27	5,996	118		2,693	813	3 546	, ,	351	1 445	1,922	909	816	1,048	36	6,224				1 775	C//'I		54		442	740	10 782	13,793	26	1,529		150		325	1,270	99	194	190	178	15	2,361	1,203		
18	· -	1,786	6		153	. 83	, cvc	2	35	90	72	58	21	41	ღ	561				4	9		2		22	99	623	832	o	79		24		∞	18	ო	15	-	19	4	89	7		
45	5 55	3,873	13		1,278	287	20	200.	197	453	962	226	240	396	14	2,418				000	000.		37		284	227	3 587	5,143	10	801		52		22	367	တ	85	. 27	50	က	582	112	!	
215	79	26,563	196		2,989.	1,809	166	r 6 7	583	1 713	2,456	1,008	1,074	2,669	65	9,568				7 550	4,330		52		1,021	3,830	40.005	49,458	201	2,766		3,493		3,469	2,171	119	517	1,169	694	83	11,695	7,904		
102	21	6,875	113		1,624	361	50	20,	456	782	1.552	969	529	779	34	4,728				1 164	, - 5 7		30		299	461	4 960	6,914	74	1,141		225		81	383	22	172	135	288	5 8	1,365	1,789		
37	; =	3,483	80		1,157	329	41	50.	52	163	383	78	94	203	5	978				777	ŧ		15		236	381	4 253	5,629	18	408		146		226	246	10	72	151	4	9	868	447		
137	57	· 21,657	89		1,622	1,449	3 99	- - -	224	1 271	1,555	579	720	2,124	41	6,514				2 727	0,10		45		791	3,257	34 926	42,753	119	2,112		3,195		3,189	1,911	62	360	906	390	40	10,053	5,761		
282	94	32,450	220		4,497	2,191	193	500,0	748	2 249	3,535	1,272	1,357	3,129	84	12,374				5 707	, , ,		91		1,340	4,117	44 448	55,703	221	3,698		3,587		3,511	2,574	133	617	1,200	739	72	12,433	8,118	- · · · · · · · · · · · · · · · · · · ·	
Antivirals	Other/unknown	TOTAL	Antineoplastics	Astnma therapies Aminophylline/	theophylline	Beta-2 agonists	Other/unknown		Cardiovascular drugs Antiarrhythmics	Anti-hypertensives	Beta-blockers	Calcium antagonists	Cardiac glycosides	Vasodilators	Other/unknown	TOTAL	Cold and cough	preparations	Acetaminophen +	decongestant/	Aspirin + acetaminophen	+ decondestant/	antihistamine	Aspirin + decongestant/	antihistamine	Expectorants/antitussives	condh/colds	TOTAL	Diagnostic agents	Diuretics	Electrolytes/minerals	Calcium salts	Fluoride (excluding	vitamins)	Iron (excluding vitamins)	Magnesium salts	Potassium salts	Sodium salts	Zinc	Other/unknown	TOTAL	Eye/ear/nose/throat preparations	Gastrointestinal	

TABLE 17. Continued

	14		Age (years)			Reason		Treated		Ċ	1		
	of	Ç	7	,	, , , , , , , , , , , , , , , , , , ,	<u> </u>	Adv	i H	ou c/N	Ming	Moderate	Major	Death
	exposures	9>	/1-9)I.<	Acc		lixu	2	None		INCORE AND	radio.	
Antacids Antidiarrheals/	6,994	6,360	262	336	6,873	62	37	329	3,920	350	18	က	-
Antidia meas/ antispasmodics	2.438	1.448	310	650	1,766	593	20	1,310	1,095	615	126	54	7
Laxatives	9,029	7,308	599	1.045	8,554	385	09	1.210	3,852	2,250	146	7	0
Other/unknown	1,061	969	86	255	866	138	51	282	525	142	23	-	0
TOTAL	19,522	15,812	1,269	2,286	18,059	1,178	198	3,131	9,392	3,357	313	32	က
Hormones and hormone													
antagonists				1		!	i		,		,	c	(
Corticosteroids	2,876	2,080	191	566	2,633	155	8 9	315	1,482	112	<u> </u>	x 0 (-
Insulin	280	32	Ξ	227	177	80	9	158	106	20	19	יסי)
Oral contraceptives	7,349	6'9'9	415	204	7,086	222	22	537	4,082	303	9	က	0
Oral hypoglycemics	691	375	22	249	534	138	4	432	376	121	48	4	0
Thyroid preparations	2,231	1,717	149	342	2,018	193	æ	643	1,327	203	47	9	α
Other/unknown	2,022	1,353	185	459	1,707	246	22	488	1,014	287	33	9	0
TOTAL	15,449	12,236	1,008	2,047	14,155	1,034	198	2,573	8,387	1,175	170	43	7
Miscellaneous drugs													
Allopurinol	506	142	9	47	173	56	2	49	126	22	8	က	0
L-Dopa and related drugs	130	70	4	55	112	16	-	53	20	50	œ	7	0
Disuffiram	535	43	50	448	189	281	51	380	86	177	53	4	0
Ergot alkaloids	487	364	86	22	364	86	55	210	225	121	20	2	0
Homeopathic/herbal													
preparations	682	523	58	123	909	41		152	382	06	13	8	0
Other	3,828	2,695	306	793	3,522	224	69	710	1,615	1,052	100	4	-
TOTAL	5,884	3,739	413	1,636	4,971	688	179	1,569	2,519	1,482	198	20	-
Muscle relaxants	2,543	505	355	1,610	934	1,499	53	1,846	290	832	245	46	0
Sedative/hypnotics/													
antipsychotics													
Barbiturates			,	1	,	0	9	0	,	č	o c	ć	c
Long acting Short/intermediate-	3,098	834	430	1,750	3,608	1,3/0	40	2,023	804	6	305	S S	ာ
acting	1.690	210	191	1,222	496	1,103	59	1,350	322	564	231	9	က
Unknown type	. 16	ဗ	-	10	S	=	0	15	0	0	80	0	-
Benzodiazepines	19,835	3,264	1,593	14,390	6,163	12,901	266	14,812	3,580	7,246	1,806	412	50
Chloral hydrate	304	9/	21	190	123	164	12	243	41	120	36	19	4
Ethchlorvvnol	307	21	15	267	52	245	-	289	24	94	99	34	က
Glutethimide	500	œ	r.	191	31	167	ო	192	17	29	20	54	2
Menrobamate	460	48	46	351	147	289	∞	354	86	151	70	21	
Methagualone	203	12	53	144	28	168	ო	180	14	53	32	5	0
OTC sleep aids	3.571	191	538	2,700	691	2,764	15	2,996	714	1,333	316	35	က
Phenothiazines	6.961	1,649	733	4,415	2,979	3,556	293	5,072	1,907	2,345	783	140	18
Other/unknown	272	58	46	191	67	192	9	219	33	63	34	10	0
TOTAL	36 926	6.345	3.648	25.821	12.390	22.930	682	27.745	7,602	12,955	3,794	855	61
1) i) ()	-	1				, I	į					

0	= 0	~ 8	82		-	0	0	ω	0	0	0	9	c	·	57		0	0	0	-		0	0		0	0	-	-	0	0	0	0	0	က	c			0	0	0	0
-	42	9 5	104		13	7	0	63	=	9	0	32	c	νσ	307		-	-	0	10		0	0		-	7	4	-	9	-	0	က	က	33	-	•	Ē	-	-	0	0
21	357	212	372		26	38	22	88	91	29	24	125	Ç	5 4	1,568		Ξ	4	S	47		16	9		-	29	30	4	32	9	80	18	50	271	. 6	2		2	30	- 1	0
77	1,152	1,515	825		463	175	93	86	231	335	93	183	Ş	, t	5,405		136	92	253	743		350	532		55	1,756	276	81	971	12	229	384	319	6,163	244	Ī		262	352	5	က
45	1,043	962	128		832	227	138	32	32	108	32	47	Ġ	8 5	3,709		260	328	1,614	2,679	•	604	5,208		130	4,294	699	879	2,866	16	2,196	639	1,089	23,471	678	5		1,460	1,897	48	15
87	2,506	1,929	2,036		959	320	186	390	462	501	102	465	106	343	10,412		20	77	248	1,402		297	120		48	564	405	159	299	24	88	191	290	4,556	204	; }		273	793	29	4
65	57	87	17		37	13	7	4	7	1	0	2	c	4 C	249		13	4	2	∞		10	က		-	80	19	8	-	8	7	80	12	110	4	•		22	54	0	0
-	1,676	1,783	1,999		632	222	116	362	465	520	80	356	7	302	8,690		80	12	32	75		28	7		7	173	163	20	3	ღ	15	30	36	673	40	2		131	273	ω,	-
148	1,981	1,824	300	•	1,179	375	239	55	134	260	117	142	99	3 8	6,885		524	538	2,865	4,168		1,202	8,902		254	8,609	1,223	1,370	5,020	45	3,862	1,324	1,897	41,803	1 270) <u>[</u>		2,632	2,709	74	22
132	1,688	1,284	2,039		514	162	86	376	329	400	85	352	0	255	7,783		86	122	412	525		203	111		28	2,380	619	139	495	55	381	177	284	6,026	267	3		281	279	~	_
24	713	1,322	121		433	160	09	15	182	213	46	114	ğ	2 6	3,541		79	38	118	181		80	79		23	781	161	42	249	6	113	142	126	2,221	9	}		260	265	വ	O
90	1,254	1,080	09		902	281	202	6	27	145	65	27	7 3	± 62	4,208		370	391	2,359	3,521		945	8,706	!	179	5,495	612	1,229	4,281	19	3,382	1,039	1,519	34,047	803	}		2,271	2,465	67	55
214	3,778	3,769	2,353		1,876	616	367	427	615	805	200	526	7	443	16,109		550	559	2,912	4,260		1,241	8,936		265	8,824	1,417	1,426	5,072	20	3,898	1,369	1,957	42,736	1 296	2		2,830	3,021	79	23
Serums, toxoids & vaccines	Amphetamines Amv/butvl nitrites	Caffeine	Cocarne Diet aids	Phenylpropanolamine	(PPA)	PPA and caffeine	Other/unknown	Heroin	rsD	Marijuana	Mescaline/peyote	Phencyclidine	rrA-containing took-	Other/unknown	TOTAL	Topicals	Acne preparations	Boric acid antiseptics	Calamine	Camphor	Camphor and methyl	salicylate	Diaper care products	Hexachlorophene	antiseptics	Hydrogen peroxide	lodine antiseptics	Mercurial antiseptics	Methyl salicylate	Podophyllin	Steroids	Wart preparations	Other/unknown	TOTAL	Veterinary drug (no human	Vitamins	Multiple vitamins (adult preparations)	No iron, no fluoride	With iron, no fluoride	With iron, with fluoride	No iron, with fluoride

TABLE 17. Continued

	Number		Age (years)			Reason		Treated					
	of							- L		Onl	Outcome		
	Exposures	9	6-17	>17	Acc	'n	Rxn	HCF	None	Minor	Moderate	Major	Death
Multiple vitamins (pediatric preparations)	preparations)								Secretary and the secretary an				
No iron, no fluoride	7,237	6,498	969	31	7,150	28	7	265	4,295	524	6	4	0
With iron, no fluoride	11,256	10,220	696	44	11,130	86	သ	1,961	6,874	1,630	70	5	0
With iron, with fluoride	420	405	17	0	417	-	0	99	280	48	_	0	0
No iron, with fluoride	1,793	1,748	39	ო	1,782	2	0	20	1,317	93	-	0	0
Vitamin A	620	493	42	77	571	59	15	69	341	56	က	0	0
Niacin	637	131	30	447	361	36	237	83	9	434	15	0	0
Pyridoxine	122	93	ත ්	19	102	15	4	16	62	13	က	0	0
Other B complex vitamins	803	609	52	131	729	37	58	83	401	129	2	0	0
Vitamin C	1,862	1,527	202	112	1,756	79	50	105	926	200	10	0	0
Vitamin D	229	181	Ξ	32	208	14	7	42	135	13	2	-	0
Vitamin E	638	528	44	63	602	23	10	45	340	40	8	-	0
Other/unknown	1,661	1,326	138	179	1,530	112	15	362	977	208	12	0	0
TOTAL	33,231	28,581	2,779	1,706	31,775	917	427	4,257	19,458	4,018	185	25	0
Unknown drug	7,163	2,737	1,133	3,091	5,027	1,586	208	3,790	2,270	1,837	365	68	0

ABBREVIATIONS: acc, accidental; adv rxn, adverse reaction; int, intentional.

* Medical outcome data were also collected in categories labeled "unknown, nontoxic," "unknown, potentially toxic," and "unrelated effect." Thus, the numbers listed here do not represent the total poison exposure experience. Patients with totally unknown age, reason or medical outcome were omitted from the respective tabulations.

Hydrochloric-acid-containing toilet bowl cleaners were implicated in six fatalities in 1986, appearing for the first time in this data base. In the group of 13 patients with ingestions of caustic agents, six (46.2%) presented with acute repiratory insufficiency from severe chemical pneumonitis.

Significant metabolic acidosis occurred early in five of the 21 deaths involving acetaminophen alone or in combination as a primary agent. Three of these cases were associated with severe hypoglycemia. Case 117 may represent an example of fatal chronic acetaminophen toxicity. In case 119, the delay in treatment resulting from failure to tolerate the oral form of *N*-acetylcysteine may have contributed to the poor outcome.

In the group of cases primarily involving cyclic antidepressants, 28 reports noted the QRS complex, and 20 (71.4%) observed it to be widened. Case 205 is sketchy but suggests a delayed catastrophic deterioration in a cyclic antidepressant overdose. Two cases were reported that demonstrated severe deterioration following the use of physostigmine in cyclic antidepressant poisoning. All five of the amoxapine cases were associated with early seizures, and at least three were refractory to conventional therapy.

The reason for the exposure was listed as accidental in 59 (14.5%) and intentional in 313 (77.1%) of the fatal cases. This trend was reversed where theophylline was the primary agent with nine (52.9%) of the 17 cases with known reason classified as accidental and at least two more as intentional but not suicidal (64.7% nonsuicidal). All of the nonsuicidal theophyl-

TABLE 18. Substances Most Frequently Involved in Human Poison Exposures*

	No.	%†
Cleaning substances	104,546	9.2
Analgesics	102,759	9.0
Plants	84,409	7.4
Cosmetics	80,214	7.1
Cough and cold preparations	55,703	4.9
Hydrocarbons	46,005	4.1
Pesticides (includes rodenticides)	45,246	4.0
Topicals	42,736	3.8
Foreign bodies	41,521	3.7
Food poisoning	38,691	3.4
Sedative/hypnotics/antipsychotics	36,926	3.3
Bites/envenomations	36,759	3.2
Chemicals	33,945	3.0
Vitamins	33,231	2.9
Antimicrobials	32,450	2.9
Alcohols	31,345	2.8

^{*} Despite a high frequency of involvement, these substances are not necessarily the most toxic, but rather, often represent only ready availability of the substance.

TABLE 19. Categories with Largest Numbers of Deaths

	No.	Percentage of All Exposures in Category
Antidepressants	100	0.7
Analgesics	82	0.1
Sedative/hypnotics	61	0.2
Stimulants and street drugs	57	0.4
Cardiovascular drugs	50	0.4
Alcohols/glycols	35	0.1
Gases and fumes	23	0.2
Chemicals	22	0.1
Asthma therapies	21	0.3
Cleaning substances	14	0.0
Insecticides/pesticides/rodenticides	14	0.0
Hydrocarbons	10	0.0

line fatalities occurred in the very young or the elderly. The average peak theophylline level was 118 μ g/ml in the acute cases and 56 μ g/ml in the chronic cases. Hemoperfusion or dialysis was employed in four (21.1%) of the 19 fatal theophylline cases.

Five of the 10 digoxin fatalities with levels recorded had peak digoxin levels less than 6 ng/ml. Case 300 may represent a case of digoxin-specific fab fragment failure in a very elderly patient. The failure to treat early with digoxin-specific fab fragments (secondary to limited availability) or the administration of grossly inadequate amounts occurred in eight of the 13 digoxin fatalities (61.5%) in which digoxin was the primary agent.

REFERENCES

- Veltri JC, Litovitz TL: 1983 annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1984;2:420–443
- Litovitz TL, Veltri JC: 1984 annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1985;3:423–450
- Litovitz TL, Normann SA, Veltri JC: 1985 annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med 1986;4:427-458

Appendix: Abstracts of Fatal Poisoning Cases

Case 3. A 60-year-old man was admitted to the hospital with gastrointestinal bleeding. While undergoing a radiologic procedure, he was inadvertently injected with 4 ml of 70% isopropanol via the mesenteric artery. The patient died three weeks later from acute peritonitis and sepsis secondary to bowel infarction from the isopropanol injection. Autopsy revealed extensive necrosis of the small and large intestines. The peritoneal cavity was occupied by a conglomerate, necrotic mass of intestine.

Case 8. A 48-year-old man presented after ingesting

[†] Percentages are based on total number of known substances (1,135,701) rather than the total number of human exposures cases.

methanol. Initially, he was comatose and in full arrest. The initial methanol level was 585 mg/dl (falling to 290 mg/dl at eight hours and 188 mg/dl at 14 hours after presentation). Potassium was 9.1 mEq/L; glucose, 466 mg/dl; PO₂, 100 mm Hg; PCO₂, 43 mm Hg; and pH 6.98. Ethanol infusion and dialysis were initiated within three hours of presentation. Hypotension persisted (40 mm Hg, systolic) despite dopamine. Dialysis was continued for four hours, discontinued for two hours, then performed for another four-hour period. The patient died 19 hours after presentation. At autopsy the ethanol level was 260 mg/dl, and methanol level was 150 mg/dl.

Case 23. A 69-year-old woman was hospitalized with a necrotizing gluteal abscess from a spider bite of one week earlier. A brown recluse spider had been found at her home and was the presumed culprit. She was treated with a variety of antibiotics in addition to incision, drainage, and local care. Two weeks following admission, the patient developed refractory lactic acidosis associated with enterococcal sepsis. Cardiac arrest ensued.

Case 25. A 26-year-old schizophrenic man told a fellow resident that he was about to take his medications (thiothixene, diphenhydramine, benztropine, methocarbamol, and ibuprofen) and that he should pray for him. Fifteen minutes later, the man collapsed in respiratory arrest. The paramedics found him with apnea and bradycardia and initiated cardiopulmonary resuscitation (CPR). In the emergency department (ED), he was treated unsuccessfully with an external and then internal cardiac pacer, fluids, and isoproterenol. He died 45 minutes after presentation. Later, a suicide note was found with a one-third-empty bottle of potassium cyanide. Cyanide was demonstrated in body tissues on postmortem examination.

Case 27. A 28-year-old man presented after an intentional ingestion of cyanide. On arrival he was unconscious with respiratory depression and seizures. The cyanide antidote kit was administered with an immediate response. He was awake and breathing spontaneously when admitted. At five hours after ingestion, he became hypotensive (91/52 mm Hg), with tachycardia (138/min) and tachypnea (48/min). He became comatose and developed respiratory and renal failure; the patient died 15 hours after ingestion.

Case 34. A 29-year-old man presented approximately 18 hours after intentionally ingesting ethylene glycol. Initial toxicologic analysis revealed ethylene glycol (154 mg/dl). The poison center was contacted 12 hours after presentation. At the time of the call, the patient was severely acidotic (pH, 7.03), was experiencing intermittent seizures, was comatose, and had been dialyzed for an unknown period of time. An ethanol infusion was initiated after prompting from the poison center. He continued to deteriorate and be-

came markedly hypotensive, necessitating a dopamine infusion. The patient died approximately 4.5 days after the ingestion. Postmortem examination confirmed the cause of death as ethylene glycol intoxication

Case 35. A 32-year-old man presented in a coma: empty bottles of aspirin/butalbital and diazepam were brought to the ED as well. On admission, his serum was negative for aspirin and barbiturates; the ethanol level was 9 mg/dl; sodium, 163 mEq/L; potassium, 4.7 mEq/L; glucose, 321 mg/dl; and blood urea nitrogen, 16 mg/dl. Multiple urinalyses were negative for crystals but became trace-positive for blood. Arterial blood-gas sampling revealed a pH of 6.9 and then 7.05 after 500 mEq of sodium bicarbonate. The poison center was first contacted to determine if diazepam was dialyzable. A serum osmolality determination was recommended and was 371 mOsm/kg H2O. An ethanol infusion was initiated. The patient seized and required dopamine for blood pressure maintenance. Because he was too unstable to transfer for hemodialysis, peritoneal dialysis was initiated. An electroencephalogram (EEG) showed no electrical activity. The patient died 24 hours later. Postmortem examination revealed acute tubular necrosis with intratubular calcium oxalate crystals (probably secondary to ethylene glycol) and fatty changes of liver with centrilobular hydropic degeneration.

Case 39. A 22-year-old man was exposed to hydrofluoric acid used to clean trucks. He sustained 27% surface area burns to his arms and back. He experienced increasing pain despite three doses of meperidine. Thirty minutes after presentation, the patient became dusky, with circumoral cyanosis and difficulty protecting his airway. Naloxone was administered, and he was intubated. Blood pressure was 90 mm Hg (palpable); pulse, 120/min; and respirations, 24/min. The cardiac monitor showed a widened QRS. All blood specimens drawn were hemolyzed. He arrested 90 minutes after presentation and could not be resuscitated. Postmortem examination revealed massive hemorrhaging in the mediastinum and distal colon. The right lung was edematous. The laboratory reported an unofficial ionized calcium level of 1.7 mg/dl because the blood pH could only be raised to 7.15.

Case 40. A 33-year-old man intentionally ingested a product containing hydrofluoric acid one hour prior to presentation. The paramedics found him unresponsive, with a pulse of 110/min; respirations, 18/min; and blood pressure, 140 mm Hg (palpable). He was given intravenous calcium chloride and sodium bicarbonate, which improved his level of consciousness. At two hours after ingestion, he arrested. Postmortem examination revealed marked pulmonary congestion and hemorrhage, mucosal sloughing in the trachea, esophageal inflammation, gastric mucosal necrosis, and

pancreatic autolysis. The blood ethanol level was 80 mg/dl, and fluoride level was 720 μ g/ml (normal, <37 μ g/ml).

Case 43. A 58-year-old woman accidentally ingested 120 ml of a diluted Christmas tree life extender containing aluminum sulfate, potassium chloride, benzalkonium chloride, and iron. She was asymptomatic, and dilution was the only treatment recommended by the poison center. The patient was determined to empty her stomach and sought ipecac from her family physician. She was given the last remaining ounce of a 4-oz bottle labeled "for vomiting." Thirty minutes after the administration of this medicine, she called the physician to report stiffness and tingling throughout her body. The paramedics found her in cardiac arrest. During intubation, her neck and jaw were noted to be stiff. The patient did not respond to the usual resuscitative measures. Postmortem examination revealed severe acute erosions and inflammation of the esophagus and gastrum. Analysis of the gastric contents and blood revealed large amounts of strychnine. Analysis of the tree life extender proved negative for strychnine. It was later learned that nux vomica had been stored in the family physician's office 30 years earlier by a previous physician tenant.

Case 48. A 67-year-old man presented one hour after intentionally ingesting 60 ml of a brass cleaner containing chromic acid, sodium bisulfate, sodium bifluoride, and ammonium chloride. Initially, he complained of chills, abdominal cramps, and watery black stools. Hypertension and dyspnea were noted on examination. Charcoal was administered. At 90 minutes after ingestion, a chest radiograph was normal. At 26 hours after ingestion, the patient developed increased dyspnea and hypotension. A central venous pressure of 6 mm Hg was observed. Vital signs remained stable, although the watery stool continued. Acute renal failure occurred, but he remained conscious and otherwise stable. He died at 115 hours after ingestion despite dialysis (initiated 90 hours after ingestion).

Case 55. A 43-year-old woman presented two hours after intentionally ingesting 32 oz of toilet bowl cleaner containing 15% hydrochloric acid. On presentation she had severe oral burns and was frothing a blue-green solution. Her blood pH was 6.7, and sodium bicarbonate was administered. She arrested and could not be resuscitated. Postmortem examination revealed oral burns, gastric perforation, and chemical pneumonia.

Case 57. A 59-year-old man was discharged from a health care facility with the diagnosis of "coin lesion" in the right lung and depression. That evening he ingested 32 ounces of a toilet bowl cleaner containing 23% hydrochloric acid and vomited spontaneously. After gastric lavage, he complained of "feeling sick," with erythematous, swollen lips. He became acidotic

and hypotensive, requiring ventilation and pressor agents. A toxicology screen was negative. On the fourth day after ingestion, he underwent total gastrectomy, pancreatectomy, splenectomy, esophagectomy, cholecystectomy and jejunostomy. Postoperatively, he experienced acute renal failure requiring dialysis, adult respiratory distress syndrome (ARDS), and sepsis. He died on the sixteenth day after ingestion. During surgery, biopsy was done of the "coin lesion" in the right lung; it was found to be benign.

Case 67. A 25-year-old man experienced arrest after an estimated 5-minute exposure to carbon monoxide from a kitchen fire. His initial carboxyhemoglobin level was 44%. At the hyperbaric facility, he was unresponsive and ventilator dependent, with a pulse of 116/min and a blood pressure of 160/102 mm Hg. The carboxyhemoglobin level fell to 22% after 60 minutes of 100% oxygen and was 2% just prior to hyperbaric oxygen. The carboxyhemoglobin level was 0% after hyperbaric oxygen. Nonetheless, he remained unresponsive. On the second day after exposure, an EEG showed no electrical activity. The EEG was unchanged 24 hours later, and respiratory support was removed.

Case 79. A 29-year-old man was trapped while cleaning a meat-processing fat vat thought to be filled with hydrogen sulfide. The patient was unconscious and was given 100% oxygen and basic life support by EMTs but could not be resuscitated. Postmortem examination showed acute tracheal bronchitis with severe pulmonary edema and hemorrhage of the lungs.

Case 82. A 30-year-old woman presented after ingesting 480 ml of a product containing 26% calcium polysulfide and 10% alpha-(p-(1,1,3,3-tetramethylbutyl) phenyl-omega-hydroxypoly (oxyethylene). She vomited spontaneously and 30 minutes later lost consciousness and seized. She was administered diazepam, sodium bicarbonate, and amyl nitrite. She was subsequently placed in a hyperbaric oxygen chamber, where she manifested a right bundle branch block and arrested. Resuscitation was unsuccessful, and she died 7.5 hours after presentation. Autopsy revealed no significant anatomic findings.

Case 83. A 35-year-old woman had been taking copper supplements for eight years on the advice of a chiropractor. She developed progressive hepatic and renal failure. She presented with coma, ascites, anuria, reticulosis, phosphaturia, choreoathetoid movements, Coombs-negative hemolytic anemia, and hypophosphatemia (1.1 mg/dl). Kayser-Fleischer rings were noted in the eyes. She was given 150 mg of dimercaprol and hemodialyzed once. There was a modest improvement in blood pressure, but later she arrested and died.

Case 85. A 30-year-old man intentionally ingested paraquat 10 hours prior to presentation. He underwent

intubation and lavage, and received charcoal hemoperfusion. He was given multiple doses of charcoal, and diatomaceous earth retention enemas were administered. He became hypoxic and hypotensive—requiring vasopressors—and then experienced upper gastrointestinal bleeding, metabolic acidosis, and anuria. The patient died on the second hospital day.

Case 87. A 64-year-old man presented after intentionally ingesting 180 ml of paraquat. He initially complained of diarrhea and experienced bradycardia and diaphoresis. Atropine was given, followed by charcoal hemoperfusion and administration of diatomaceous earth. He subsequently developed renal failure, fixed and dilated pupils, and hypotension, requiring vasopressors. He had evidence of esophageal burns and pulmonary fibrosis and died 24 hours after exposure.

Case 88. A 79-year-old woman presented 9.5 hours after intentionally ingesting 40 ml of carbon tetrachloride. She complained of vomiting and diarrhea although alert with normal vital signs. The leukocyte count was 28,300/mm³; serum glutamic oxaloacetic transaminase (SGOT), 149 U/L; and total bilirubin, 2.1 mg/dl. She was loaded with 9.800 mg N-acetylcysteine, followed by 4,900 mg every four hours, orally. On the second hospital day, her condition rapidly deteriorated. She developed metabolic acidosis, weakness, lethargy, and decreased renal function. The serum SGOT was 1,404 U/L; blood urea nitrogen, 38 mg/dl: creatinine, 2.1 mg/dl; and bilirubin, 2.5 mg/dl. She developed pulmonary congestion and hypotension. At 44 hours after ingestion, she developed asystole and died.

Case 92. A 12-year-old boy, with cerebral palsy and mental retardation, accidentally ingested 300 to 360 ml of lamp oil. Initially, he experienced vomiting and coughing, and was cyanotic. The chest radiograph showed a total white-out of the right lower lobe. Secretions were oily and pinkish. The patient required intubation and ventilation. By the third day after exposure, the secretions had become copious and bloody. By the sixth day after exposure, the patient had three chest tubes for pneumothoraces. Dopamine was required for hypotension. By the ninth day after exposure, the patient had a total of five chest tubes, required positive end expiratory pressure (PEEP) at 16 cm H₂O and a ventilatory rate of 48/min. On the tenth day after exposure, he developed diffuse subcutaneous crepitus with decreased cardiac and urinary output, and eventually arrested.

Case 93. A 13-month-old boy ingested paint thinner (100% mineral spirits). Paramedics observed asystole on arrival but achieved sinus rhythm after intubation. A frothy substance was suctioned from the endotracheal tube. The blood pressure was 84/0 mm Hg. Naloxone, dextrose, and sodium bicarbonate were administered. Arterial blood gases revealed a pH of 6.9;

PCO₂, 53 mm Hg; and PO₂ 71 mm Hg with positive end-expiratory pressure (PEEP). Diazepam and phenobarbital were administered for seizure activity and dopamine for hypotension. A chest tube was inserted five hours after ingestion. Later, the blood pressure was 95/16 mm Hg; pulse, 164/min; respirations, 56/ min; pH, 7.51; PCO₂, 13 mm Hg; and PO₂, 471 mm Hg. The drug screen was negative. Urine output ceased and did not respond to albumin or furosemide. Sixteen hours after ingestion CPR was initiated for hypotension and dysrhythmias, resulting in normal sinus rhythm. The patient experienced three more episodes of bradycardia and hypotension, which responded to drug therapy until he died 22.5 hours after ingestion. Arterial blood gases just prior to death were pH, 7.17; PCO₂, 48 mm Hg; and PO₂ 75 mm Hg. Postmortem examination revealed chemical pneumonitis.

Case 98. A 2-year-old boy presented several hours after exposure to aldicarb. Increased secretions, respiratory depression, miosis, hypothermia, and evidence of aspiration were noted. Initial red blood cell cholinesterase levels were depressed. He arrested 14 hours after exposure and was successfully resuscitated. Large doses of atropine resulted in a heart rate of 160/ min without resolution of rales. An atropine infusion was maintained for three days. Dopamine and insulin were also required. Blood glucose ranged from 150 to 400 mg/dl. On the third day after exposure, exchange transfusions were performed. Seizures developed on the sixth day and were controlled with diazepam. EEGs indicated no brain activity. Life support systems were discontinued on the thirteenth day. Massive amounts of aldicarb and its metabolites were found in the urine.

Case 101. A 41-year-old (96-kg) man was being admitted to a mental health facility when he drank 60 ml of shampoo containing lindane. He vomited spontaneously then was given ipecac syrup. Thirty minutes later, he seized. On arrival at the hospital, he was lethargic and diaphoretic, with a blood pressure of 180/80 mm Hg; pulse, 116/min; and respirations, 16/ min. Five minutes later, he arrested and was resuscitated. He underwent lavage and was given lidocaine, phenytoin, charcoal, cholestyramine, and sorbitol. Chest radiograph initially revealed a right lower lobe infiltrate that progressed to diffuse bilateral infiltrates. Clindamycin, tobramycin, and hydrocortisone were added. He remained flaccid and developed pitting edema of the upper extremities. On the fifth day, his creatine phosphokinase peaked at 2,795 U/L, and he was extubated. Arterial blood gas testing revealed a pH of 7.47; PCO₂, 32 mm Hg; and PO₂, 82 mm Hg on 40% oxygen with respirations of 44/min. On the seventh day, he arrested and could not be resuscitated. Lindane levels were 1.3 µg/ml on admission and 0.1 µg/ml on the sixth day. The levels at autopsy were blood, $0.02 \mu g/ml$; fat, 1.45 mg/kg; heart, $0.26 \mu g/kg$; and liver, $0.16 \mu g/kg$.

Case 102. A 16-year-old boy, intent on burglary, entered a house following methyl bromide fumigation for termites. He was inside for approximately 45 minutes. One hour after leaving the house, be began to vomit and complained of being dizzy. On presentation, his heart rate was 160/min, and pH was 7.0. He experienced respiratory failure from marked pulmonary edema. Benzodiazepines and phenytoin were used to treat seizures. At 16 hours after inhalation he arrested. He was resuscitated but died on the second day after inhalation.

Case 107. A 62-year-old woman presented two hours after intentionally ingesting a furniture-refinishing agent containing 20% methanol, 36% acetone, 20% toluene, and 24% isopropanol. She was unresponsive and apneic with a blood pressure of 60 mm Hg, a pulse of 104/min, and no urine output. Levels on admission were methanol, 104 mg/dl; acetone, 114 mg/dl; isopropanol, 101 mg/dl; and ethanol, 108 mg/dl. Blood pressures remained at 50 mm Hg in spite of dopamine and norepinephine administration. Charcoal was administered and an ethanol infusion initiated, but the family refused dialysis. She remained unresponsive and hypotensive until her death 48 hours after ingestion.

Case 109. A 40-year-old man presented after ingesting a "wild" or "mock" cucumber (Echinocystis) several hours earlier. He developed progressive leg and abdominal cramping. Profound shock and tachycardia were treated with antishock trousers and fluids. Dilated pupils and a hematocrit level of 81% were noted. The poison center determined that a mock cucumber was nontoxic, and information on a wild cucumber was not available. The patient developed disseminated intravascular coagulation and refractory shock despite aggressive supportive therapy. Repeated doses of physostigmine and naloxone were ineffective, and he died several hours later. The medical examiner found seeds in the stomach, identified as Marah oreganus (common name, coast manroot). Apparently, the patient had prepared a tea for its hallucinogenic properties. This plant resembles a lemon cucumber. Some of the Marah plants contain flavinoids. This particular plant contained cucurbitacin, which is cytotoxic.

Case 111. A 35-year-old man complained of epistaxis, hematuria, gingival bleeding, and bilateral back pain. Examination revealed a blood pressure of 124/70 mm Hg; pulse, 72/min; temperature, 36.8°C; diffuse ecchymosis on left side of body; and an inappropriate affect. Laboratory results revealed a prothrombin time of 60 seconds (control, 12.4 seconds), a bleeding time greater than 15 minutes, and a platelet count of 147,000/mm³. An ingestion was denied, although he

later reported "dreams" of bleeding that required massive doses of vitamin K, and he was vague on questions regarding ingestion of brodifacoum. Treatment consisted of six units of fresh frozen plasma and massive subcutaneous doses of phytonadione over 24 hours, with gradual return of the prothrombin time toward normal. Oral phytonadione was instituted with a prothrombin time of 15.6 seconds (control, 12.4 seconds) on discharge five days later. He returned to clinic for follow-up, but refused laboratory work. Seventeen days after discharge, he was found in status epilepticus. Computed tomographic (CT) scanning revealed a massive intradural bleed with multiple small hemorrhages. He was pronounced brain dead in the ED with a prothrombin time of 60 seconds (control, 12.6 seconds) and partial thromboplastin time of 86.6 seconds (control, 26.8 seconds).

Case 112. An 18-year-old man presented one hour after ingesting a rodenticide. He was comatose, with tonic-clonic activity of both upper and lower extremities. He arrested and was resuscitated in the field. In the ED, he was evanotic, with a pulse of 122/min; blood pressure, 86 mm Hg; temperature, 38.1°C; and no respirations. Laboratory results included a pH of 6.51; PO₂, 269 mm Hg; PCO₂, 63 mm Hg; creatine phosphokinase, 430 U/L; glucose, 683 mg/dl; and serum lactate, 39.5 mmol/L. The urine toxicology screen was positive for strychnine only. Treatment included sodium bicarbonate, diazepam, fluids, dopamine, and ventilation. Gastric lavage was performed, and charcoal and magnesium citrate were administered. Tonic muscle activity was controlled with pancuronium bromide after no response to phenobarbital. At 12 hours, hyperthermia developed and was treated with cooling blankets and ice packs. Rhabdomyolysis resulted in renal failure. ARDS, requiring PEEP, was complicated by a pneumothorax. Brainstem herniation secondary to acidosis and anoxia were diagnosed. The patient was pronounced dead on day 5 from refractory hypotension and bradycardia.

Case 115. A 20-year-old man presented with vomiting, abdominal pain, and tachycardia 40 hours after an intentional overdose of acetaminophen. He had notified his girlfriend of his intent, but denied the ingestion to police who went to his house to check on him. Oral N-acetylcysteine was initiated. Admission laboratory findings included an SGOT of 2,645 U/L; alkaline phosphatase, 84 IU/L; bilirubin, 4.5 mg/dl; and acetaminophen, 67 μg/ml. On the fourth day after ingestion, the patient became lethargic. Repeat laboratory testing revealed an SGOT of 26,700 U/L; uric acid, 52 mg/dl; and bilirubin, 6.5 mg/dl. He died on the fifth day after ingestion.

Case 117. A 25-year-old man, who had been taking acetaminophen throughout the day prior to hospitalization, presented with right-sided head pain. His wife

stated he had been taking two to three acetaminophen every hour. His acetaminophen level, four hours after the last dose, was 22 µg/ml. The admission laboratory findings included an SGOT of 9,410 U/L; serum glutamic pyruvic transaminase (SGPT), 2,290 U/L; and prothrombin time, 18.3 seconds (control, 11.8 seconds). N-acetylcysteine was given, and he did well until he suddenly deteriorated and died.

Case 119. A 29-year-old woman presented 12.5 hours after intentionally ingesting 24.5 g of acetaminophen. The patient vomited spontaneously. The acetaminophen level was 175 µg/ml 13 hours after ingestion, and N-acetylevsteine administration was begun. The serum salicylate level was 2.7 mg/dl. She continued to vomit and required metoclopramide, promethazine, and nasogastric tube insertion to retain the N-acetylcysteine. She developed progressive hepatic and renal insufficiency requiring lactulose, a proteinsparing diet, and dialysis. Approximately 30 hours after ingestion, the SGOT was greater than 5,000 U/L; SGPT, greater than 5,000 U/L; and lactate dehydrogenase, greater than 6,000 U/L. On the third hospital day, prothrombin time was 77 seconds (control, 11 seconds), and arterial ammonia was 280 mmol/L, rising to 597 mmol/L on the fourth day. She died from multiple organ failure on the fifth hospital day.

Case 121. A 65-year-old woman presented with a history of lethargy for two days prior to an intentional ingestion of acetaminophen. She was unresponsive on examination. The seven-hour acetaminophen level was 739 µg/ml, and the 16-hour level was 503 µg/ml. Toxicology screening was positive only for acetaminophen and benzodiazepines. The patient was started on oral N-acetylcysteine by 12 hours after ingestion. Admission laboratory findings included an SGOT of 715 U/L; bilirubin, 1.5 mg/dl; prothrombin time, 13 seconds; glucose, 29 mg/dl (240 mg/dl after 2 g dextrose); pH, 7.08 (after 100 mEq of bicarbonate); PCO₂, 30 mm Hg; and PO₂, 106 mm Hg. On the second day after ingestion, intubation and pressor therapy (dopamine and levarterenol) were required. The patient developed progressive cardiac and renal failure and died later that day.

Case 123. A 42-year-old woman presented with lethargy three days after intentionally ingesting acetaminophen, nail polish remover (87% acetone), and a liquid cough and cold preparation. Vital signs were a temperature of 36°C; pulse, 130/min; respirations, 45/min; and blood pressure, 120/70 mm Hg. Hepatic and renal failure developed with coagulation defects, hypoglycemia, and encephalopathy. Hypotension did not respond to 4 L of saline but did respond to dopamine. Naloxone, 50% dextrose, sodium bicarbonate, and calcium chloride were administered. The initial acetaminophen level was 3.3 μg/ml; alkaline phosphatase, 241 IU/L; creatinine, 6.1 mg/dl; blood urea ni-

trogen, 20 mg/dl; albumin, 3.5 g/dl; salicylate level, 34 mg/dl; lactic acid, 15.4 mEq/L; CO_2 , 12 mEq/L; and glucose, 42 mg/dl. A full course of oral N-acetylcysteine was given. Hemodialysis and filtration were done to treat renal failure. Ten days after ingestion, a CT scan documented severe cerebral edema. The patient progressively deteriorated and died 21 days after ingestion.

Laboratory Tests

Day	SGOT (U/L)	SGPT (U/L)	Bilirubin (mg/dl)	Prothrombin Time (seconds)
3	20,920	2,950	7	43
6	1,278	654	9	21
8	296	330	10	23
11	118	123	18	15
12	88	81	16	
20	_	_	31	_
21	_	_	36	

Case 128. A 65-year-old woman presented six to 12 hours after intentionally ingesting up to 80 500-mg acetaminophen 15-mg oxycodone capsules. Initially, she was comatose, with apnea, hypotension, and fixed and dilated pupils. Gastric lavage was performed and charcoal given. Naloxone (1.6 mg) was given with no response. The admission acetaminophen level was 1,000 µg/ml. N-acetylcysteine was administered, and levarterenol was required to maintain the blood pressure. On the first day after ingestion, the patient remained on the ventilator and pressor infusion and developed signs of impending liver failure. She died later that day.

Case 153. A 23-year-old man presented two hours after intentionally inhaling isobutyl nitrite and ingesting salicylates. On arrival he was hallucinating and vomiting. Salicylate concentration was 115 mg/dl. Three hours after presentation, cyanosis appeared, which was unresponsive to oxygen and methylene blue. It was learned that the patient received 70 ml of methylene blue (1%) instead of the recommended 7 ml. He arrested eight hours after ingestion and died. The methemoglobin level was 30% prior to the arrest.

Case 157. A 57-year-old man presented two days after intentionally ingesting 15 mg of colchicine. He complained of vomiting, diarrhea, and anorexia and was hypotensive and febrile. Laboratory findings included leukocytosis and elevated renal function parameters. Multiple doses of charcoal were attempted, but vomiting continued during the next 24 hours. The hypotension was refractory to fluids and necessitated dopamine. Renal function deteriorated, and aspiration pneumonia developed, requiring antimicrobial therapy. On the fourth day after ingestion, bleeding

occurred from multiple sites and renal failure required peritoneal dialysis. He experienced leukopenia and ARDS and died on the fifth day after ingestion.

Case 159. A 78-year-old man presented with diarrhea, weakness, and inability to walk. He had received a prescription for colchicine 10 days prior to admission, and only 14 of 60 tablets remained. His heart rate was 98/min; blood pressure, 104/70 mm Hg; respiration, 14/min; and temperature, 35.8°C. Mucous membranes were dry, and his skin "tented" secondary to dehydration. There was no sensation in the lower extremities, and no deep tendon reflexes, only sensation around the trunk. Laboratory studies revealed renal insufficiency (creatinine, 5.6 mg/dl; blood urea nitrogen, 54 mg/dl), leukopenia (leukocyte count, 1,600/mm³), and thrombocytopenia (platelets, 110,000/mm³). He became hypotensive but was otherwise stable for 48 hours. Then he became progressively unresponsive, went into third-degree heart block and arrested. Postmortem examination revealed bilateral lower lobe congestion, mild splenomegaly, and mild hepatic fibrosis.

Case 171. A 37-year-old man was admitted to the psychiatric ward of a hospital. Two days later he was found in cardiopulmonary arrest. He responded to intubation, lidocaine, and naloxone. Blood pressure was 90 mm Hg, and body temperature was 35.8°C. Toxicologic screen revealed diazepam, 1.67 µg/ml; nordiazepam, 6.29 µg/ml; propoxyphene, 1,021 ng/ml; norpropoxyphene, 2,786 ng/ml. Seizures were refractory to phenytoin, phenobarbital, and paraldehyde but responded to general anesthesia. Aspiration pneumonia occurred, and the patient progressively deteriorated over the next two weeks.

Case 174. A 31-year-old man presented with an altered mental status, hyperthermia (42.7°C), tachycardia, and hyperkalemia (7.4 mEq/L). The delirium was treated with haloperidol and benztropine. It was later learned that he ingested benztropine several hours earlier. Toxicologic screen was positive for benzodiazepine, nicotine, amphetamines, and phenobarbital. Multiple doses of physostigmine were given without result. Dantrolene sodium was used for the hyperthermia. He developed refractory ventricular arrhythmias and died.

Case 176. A 19-year-old man presented four hours after intentionally ingesting carbamazepine, temazepam, aspirin, and levothyroxine. He was unconscious, with a blood pressure of 120/80 mm Hg; a pulse of 130/min, and shallow respirations. Intubation, ventilation, and lavage were done, and charcoal and a cathartic were administered. A grand mal seizure was treated with diazepam, and dopamine was required for persistent hypotension. The admission carbamazepine level was 120 μg/ml, which decreased to 63.6 μg/ml after three hours of charcoal hemoperfusion. Seven

hours later, the level rebounded up to $108~\mu g/ml$ then fell to $75~\mu g/ml$ after three additional hours of hemoperfusion. Subsequently, he arrested and was initially resuscitated but died after a second cardiac arrest 35 hours after ingestion. Blood toxicology results were also positive for salicylates 21 mg/dl and temazepam 178 ng/ml. The thyroxine concentration was 21.9 $\mu g/dl$. Postmortem examination revealed pulmonary edema.

Case 177. A 34-year-old mentally handicapped man presented in a coma and seizures. Vital signs included a blood pressure of 50 mm Hg and a pulse of 75/min. He underwent intubation, ventilation, and lavage. Dopamine, levarterenol, and charcoal were administered. The initial carbamazepine level was 54.8 µg/ml. Seizure activity persisted despite diazepam, phenytoin, and phenobarbital administration. Ventricular tachycardia was treated with lidocaine. At seven hours after the first poison center call, hyperthermia (41.9° C) occurred and was treated with acetaminophen, cooling mats, and ice packs. By 16 hours, the seizure activity had ceased, and the temperature was 38.1° C rectally; pulse, 120/min; and blood pressure, 112/60 mm Hg. By 28 hours, the carbamazepine level had dropped to 12.7 µg/ml. At 52 hours, he was obtunded and anuric. He died at 72 hours. (All times are referenced to the first poison center contact.)

Case 179. A 3-year-old boy presented one hour after ingesting six or more phenytoin capsules. He was ataxic, and emesis was induced with ipecac syrup. Five hours after ingestion, the child was agitated, with tachycardia (130/min) and tachypnea (40/min). Nine hours after ingestion, he experienced a respiratory arrest and was resuscitated. Coma was noted 12 hours after ingestion. A toxicology screen also revealed benzyl alcohol. Multiple doses of charcoal were administered. Pertinent laboratory findings included sodium, 125 mEq/L; potassium, 2.9 mEq/L; arterial pH, 7.3; and PCO₂, 30 mm Hg. At 24 hours postingestion, diabetes insipidus developed, requiring vasopressin. On the third day after ingestion, an EEG showed "minimal" activity; he died later that day.

*	Plasma Phenytoin	
Time After	Levels	
Ingestion	(μg/ml)	
1 h	50	
12 h	47	
18 h	43	
24-48 h	40	

Case 205. A 59-year-old man was admitted unconscious after ingesting amitriptyline/perphenazine, triazolam, and diazepam. He underwent intubation and lavage, and was given charcoal and a cathartic. His

vital signs were "unremarkable," with a pulse of 80/min. He was extubated nine hours after admission. Multiple doses of charcoal were given. He was awake and walking 24 hours after admission. Unexpectedly, he seized, then arrested. The coroner concluded that the death was from cardiac dysrhythmias.

Case 206. An 18-year-old woman intentionally ingested amoxapine. At first she was alert and responsive. She was given ipecac and experienced seizures prior to emesis. The seizures continued despite diazepam, phenytoin, phenobarbital, and sodium bicarbonate administration. She underwent intubation, ventilation, and lavage, and was given charcoal, a cathartic, and physostigmine. The vital signs and cardiac rhythm were normal, and the seizure activity stopped. Later she was described as "bleeding from every orifice" and was unresponsive to any stimuli. The patient died on the third day after ingestion.

Case 209. A 60-year-old woman presented two hours after ingesting amoxapine. A sinus tachycardia was noted, and subsequently she seized. The seizures responded to diazepam, and she was loaded with phenytoin. She underwent intubation and lavage, and was given charcoal, a cathartic, and sodium bicarbonate. Arterial blood gases obtained two hours after ingestion disclosed a pH of 6.97. Five hours after ingestion, seizures recurred and were unresponsive to diazepam, phenytoin, and phenobarbital. Physostigmine was administered, resulting in bradycardia and hypotension. Levarterenol was administered without response, and the patient arrested and died.

Case 252. A 64-year-old woman presented the morning after intentionally ingesting lithium carbonate. She complained of nausea and vomiting but was alert, oriented, and without tremors. The electrocardiogram (EKG) was normal, and the lithium level was 8.5 mEq/L. Charcoal and a cathartic were administered. Urine output was low. The lithium level on the second day after ingestion was 6 mEq/L. The patient continued to be alert and oriented. Mannitol and intravenous fluids were given, and urine output increased to 100 ml/h. Vital signs and the EKG were normal. On the third day after ingestion, she became more lethargic, with a lithium level of 7.1 mEq/L. The urine output was 20 ml/h, and the blood urea nitrogen and creatinine were 47 mg/dl and 4.2 mg/dl, respectively. The patient was hemodialyzed. On the fourth day after ingestion, she arrested and was resuscitated. The lithium level at that time was 5.6 mEq/L. Hypotension (60 mm Hg) occurred and was refractory to levarterenol. Electromechanical dissociation led to her death on the fifth day after ingestion. The toxicologic screen was positive only for lithium.

Case 260. A 24-year-old man presented 14 hours after intentionally ingesting 1.5 g of phenelzine. While initially awake and alert, by 24 hours after ingestion

he was comatose and tremulous with tachycardia (170/min). His blood pressure was normal, but he experienced frequent seizures. The supraventricular tachycardia was treated with propranolol but converted to refractory ventricular tachycardia. He died on the second day after ingestion.

Case 261. A 39-year-old man presented 10 hours after intentionally ingesting phenelzine (3.8 to 8.8 mg/kg). He was diaphoretic and tremulous. Blood pressure was 104/50 mm Hg; pulse, 64/min; respirations, 16/min; and temperature, 35.9° C. The toxicology screen revealed trifluoperazine and phenelzine. Lavage was performed, and he was given serial doses of charcoal, a cathartic, and fluids. Increasing confusion and rigidity required diazepam and restraints. By 36 hours after ingestion, his pulse was 170/min, blood pressure fell to 70 mm Hg, and body temperature was 42° C. The hypotension was refractory to usual therapy including dopamine and norepinephrine. Hyperthermia responded to acetaminophen, cold packs, a cooling blanket, and dantrolene. Refractory pulmonary edema, disseminated intravascular coagulation, and hypercarbia occurred. The pressure fell to 40 mm Hg and was unresponsive to calcium and glucagon. At 43 hours after ingestion, fatal electromechanical dissociation ensued. Postmortem examination revealed marked pulmonary edema and a blood phenelzine level of 140 ng/ml.

Case 263. A 44-year-old man was found unresponsive after intentionally ingesting tranylcypromine (up to 900 mg). He was tremulous with mydriasis. Vital signs included respirations 18/min; blood pressure, 102/72 mm Hg; temperature, 40.4° C; and pulse, 130/ min. The EKG demonstrated atrial fibrillation with a QRS duration of 0.11 seconds. He underwent intubation and lavage, and was given charcoal and a cathartic. Arterial blood gases revealed a pH of 7.27, PCO₂, 57; and PO₂, 100 mm Hg. Three hours after admission of the patient, a grand mal seizure was treated with diazepam and phenytoin. Body temperature increased to 42.5° C. After the seizure, he became hypotensive but responded to fluids and dopamine. He was acidemic and anuric. Intermittent wide complex arrhythmias developed, which rapidly deteriorated to ventricular fibrillation. He died from refractory electromechanical dissociation four hours after presenta-

Case 265. A 67-year-old diabetic woman (history of congestive heart failure) intentionally ingested trazodone. The patient was on digoxin therapeutically and had a digoxin level of 2.0 ng/ml on admission. Bradycardia (50/min) with a good pulse was noted. The QTc interval was 0.54 seconds, and QRS was 0.1 seconds. The serum trazodone level was 5,800 ng/ml. Later that day, the patient experienced ventricular tachycardia, then fibrillation. She was intubated then shocked into

asystole. Isoproterenol resulted in a sinus rhythm with pulses. "Torsades de Pointes" developed, which responded to overdrive pacing. Rigidity and decorticate posturing were observed. On the fourth day after ingestion, she was extubated, and the pacer was removed. She was very lethargic and answered some questions appropriately. The QT interval gradually returned to normal (0.43 seconds). On the seventh day after ingestion, she arrested three times. Thereafter, she was unresponsive and died on the nineteenth day after ingestion.

Case 267. A 15-year-old girl presented two to four hours after intentionally ingesting 6,250 mg of diphenhydramine. She was seizing, and had a temperature of 41.8° C, a pulse of 160/min, and marked acidosis. The seizures was unresponsive to diazepam, phenytoin, and physostigmine, so the patient was paralyzed with pancuronium. She underwent lavage and was given charcoal. The pulse decreased to 120/min after physostigmine. The patient developed refractory asystole and was pronounced dead five to seven hours after ingestion. The postmortem blood diphenhydramine level was 9.7 μg/ml and liver was 52.6 μg/g.

Case 269. A 12-month-old girl ingested 1 g of chloroquine. Unaware of the toxicity, the parents allowed the child to go to sleep. They found her unresponsive 30 minutes later. The child presented in a full cardio-pulmonary arrest. She was resuscitated but manifested refractory hypotension. Ventilatory support was terminated on the third day after ingestion.

Case 271. A 6-month-old boy was hospitalized for pulmonary insufficiency from bronchopulmonary dysplasia and right ventricular hypertrophy. The admitting theophylline level was 2 μ g/ml, and the dosage was increased. Within two days, the level increased to 24 μ g/ml, and the dosage was decreased. However, 24 hours later the level was 40 μ g/ml, and he manifested tachycardia and shock. Theophylline was discontinued, and charcoal and a cathartic were administered. Seven hours later the level decreased to 33 μ g/ml, but the pulse was 190/min. Three hours later refractory asystole occurred, and the patient died.

Case 273. A 15-year-old girl presented after intentionally ingesting 30 g of sustained-action theophylline. The initial blood level was 88 μ g/ml. She was obtunded, with tachycardia (120 to 130/min) and hypotension (100 mm Hg). Charcoal hemoperfusion was performed but the theophylline level was 190 μ g/ml afterward. Ventricular fibrillation occurred but was refractory to treatment. She was placed on cardiac bypass from which she could not be weaned.

Case 274. A 17-year-old girl presented several hours after intentionally ingesting 2.9 g of sustained-release theophylline. Her pulse was 190/min and blood pressure was 110/80 mm Hg; and she seized. Her initial theophylline concentration was 93 µg/ml, and a

second level was 117 μ g/ml. Fourteen hours after ingestion she was given pancuronium and thiopental for the seizures and dopamine and levarterenol for hypotension. Body temperature reached 40.1° C despite external cooling. Hemodialysis was not performed at this time because of extreme hypotension. On the second day after ingestion, her theophylline level was 80 μ g/ml. She developed refractory ventricular fibrillation and was pronounced dead 38 hours after ingestion. The urine toxicology screen revealed no other drugs.

Case 288. A 72-year-old woman had been chronically abusing ethchlorvinyl and theophylline. She presented with ataxia, vomiting, and multifocal atrial tachycardia (140/min). The theophylline level was 40 μ g/ml with a potassium level of 1.9 mEq/L. The theophylline level decreased to 29 μ g/ml, and the potassium level increased to 2.9 mEq/L. She developed respiratory failure from aspiration pneumonia and sepsis. The potassium eventually increased to 4.2 mEq/L before she died.

Case 291. A 65-year-old woman presented with suspected amiodarone toxicity. The EKG revealed a sinus arrest with a ventricular escape rate of 40/min. Atropine, isoproterenol, and glucagon were ineffective. The pulse remained at 40/min, with a palpable blood pressure of 80. Three hours after admission it was decided that no further life-sustaining measures were to be initiated. The serum amiodarone level was 14 μ g/ml (toxic is 2.5 to 6.7 μ g/ml). The patient died 24 hours after admission.

Case 294. A 63-year-old woman presented after intentionally ingesting 1 g of captopril and some ethanol. She was comatose with miotic pupils, a blood pressure of 72 mm Hg, and a pulse of 104/min. Arterial blood gases revealed a pH of 7.17; PO₂, 45 mm Hg; and PCO₂, 45 mm Hg. She underwent intubation and lavage, and was given fluids, naloxone, dopamine, and charcoal. The hypotension did not respond, and she died within six hours of presentation. Blood ethanol at postmortem examination was 238 mg/dl.

Case 296. A 54-year-old man presented two hours after intentionally ingesting digoxin. The pulse was 36/min; temperature, 36.1° C; respirations 24/min; and blood pressure, 96/60 mm Hg. The digoxin level was 30.8 ng/ml, and potassium was 6.1 mEq/L. Lavage was performed and phenytoin infused. Eight hours after ingestion, he became confused and suddenly developed a complex ventricular dysrhythmia. He died nine hours after ingestion without receiving digoxin-specific Fab fragments.

Case 299. A 79-year-old male physician was admitted to rule out a myocardial infarction. A routine serum digoxin level, available seven hours after admission, was 24.9 ng/ml. While the digoxin-specific antibody was en route, he arrested but was revived.

He was stabilized on dopamine, epinephrine, and a pacemaker. A digoxin level drawn 17 hours after admission was 16.4 ng/ml. The digoxin-specific Fab fragments were administered 19 hours after admission with little improvement. He experienced arrest again 39 hours after admission and died. An autopsy did not identify any other likely cause of death.

Case 303. A 78-year-old woman became toxic on prescribed digoxin and methyldopa. She complained of nausea and vomiting, with confusion and decreased bowel sounds noted. An idioventricular rhythm (40/min) was observed, and the blood pressure was 90 mm Hg. The digoxin level was 3.9 ng/ml, and potassium was 3.9 mEq/L. Atropine increased the pulse to 80/min with occasional premature ventricular beats. The blood pressure increased to 110 mm Hg with a dopamine infusion. She appeared stable for several hours until she developed sudden refractory ventricular fibrillation. The patient did not have a repeat digoxin level assay done and never received digoxin-specific fab fragments.

Case 304. A 48-year-old man intentionally ingested digoxin, metoprolol, and ethanol. On arrival he was awake and moaning with a pulse of 30/min. The digoxin level was 10 ng/ml, and digoxin-specific antibodies were requested. While awaiting their arrival, a pacemaker was inserted but did not capture. The patient died seven hours after presentation, before digoxin-specific antibodies could be procured.

Case 312. A 21-year-old woman presented one hour after intentionally ingesting up to 2 g of propranolol and 12 g of flecainide. These drugs were prescribed for her chronic ventricular tachycardia. Her blood pressure was 70/40 mm Hg; pulse, 70/min; respirations 20/ min. She developed first-degree heart block 80 minutes after ingestion. She was treated with a theophylline infusion, a transcutaneous pacer, atropine, and dopamine. Two hours after ingestion, she was comatose, the QRS widened, and third-degree heart block was diagnosed. Three hours after ingestion, asystole occurred, which was unresponsive to standard pharmacologic intervention, glucagon, pacing, and open-heart massage. She was pronounced dead 6.5 hours after ingestion. The serum flecainide level at the time of death was 3.2 µg/ml, and postmortem levels were blood, $10.9 \mu g/ml$, and liver, $256 \mu g/g$. The postmortem blood propranolol level was 1.1 µg/ml.

Case 328. An 18-month-old child presented four hours after ingesting ferrous sulfate. The child was unconscious, and the serum iron level six hours after ingestion was 23,000 µg/ml. Intravenous deferoxamine was initiated at 15 mg/kg/h. At 12 to 16 hours after ingestion, hypotension occurred, which responded to fluids. At 24 hours after ingestion, an acute surgical abdomen was diagnosed. An exploratory laparotomy revealed 40 cm of necrotic bowel at the distal ileum,

with perforation and peritonitis. Broad spectrum antibiotics were administered. The serum iron at 24 to 30 hours after ingestion was 200 $\mu g/dl$. By 48 to 72 hours after ingestion, elevated liver function tests, bilirubin, and prothrombin time were noted. By 72 hours after ingestion, the child's sensorium cleared. All liver functions returned to normal with supportive care. Respiratory insufficiency beginning seven days after exposure led to the patient's death on the fourteenth day after ingestion.

Case 330. A 40-year-old woman presented after ingestion up to 40 mg of loperamide and an unknown amount of salsalate. Lavage recovered many green tablet particles. She had tachycardia, with a blood pressure of 100/60 mm Hg and respirations of 36/min. Naloxone and sodium bicarbonate were administered. The salicylate level was 77 mg/dl initially and 90 mg/dl 2.5 hours later. At 21 hours after presentation, refractory asystole developed, and the patient died.

Case 331. A 16-year-old bulimic girl presented one hour after intentionally ingesting 8 to 16 ounces of baking soda (sodium bicarbonate) in an attempt to induce vomiting. Lavage was attempted without success because of inability to intubate the stomach. Severe gastrointestinal distension compressed and damaged vital organs. She died 16 hours after ingestion of complications from an infarcted small intestine.

Case 344. A 31-year-old psychotic man received 10 mg of haloperidol intramuscularly every four hours for 24 hours to control his behavior. He was noted to be lethargic all day. He was found in his room, in four-point restraints, in full cardiorespiratory arrest. Resuscitation was unsuccessful. Serum haloperidol level at postmortem examination was $0.1~\mu g/ml$, and no other cause of death was found.

Case 353. An adult woman was found unconscious and hyperthermic (41.7°C). She had been an inpatient at a state mental institution, where thioridazine administration, 150 mg four times daily, was begun three days earlier. She developed ventricular tachycardia with numerous arrests. Despite vigorous resuscitative efforts, her temperature remained between 39.3° and 41.7°C, and extensive multisystem failure occurred. She died two days after admission. The cause of death, as listed by the coroner, was neuroleptic malignant syndrome secondary to thioridazine.

Case 361. A 1-year-old boy presented 15 minutes after ingesting some of his mother's diet pills. He initially convulsed seizure and was treated with diazepam. He was tremulous with a pulse of 200/min; blood pressure, 120/70 mm Hg; and temperature, 38.3° C. Gastric emptying was induced with ipecac syrup; no pill fragments were seen, however. Rigidity, hyperreflexia, and tachycardia (190/min) were noted. During aeromedical transfer 30 hours after ingestion, the child developed status epilepticus and hypoten-

sion (52 mm Hg). He arrested and was resuscitated, underwent lavage, and was given dopamine and albumin. The toxicologic screen showed a caffeine level of 110 mg/dl at 40 hours after ingestion. He developed diabetes insipidus requiring vasopressin. Phenobarbital, glucose, and insulin were administered. The caffeine level after three fourths of an exchange transfusion was 161 mg/dl. A CT scan showed diffuse cerebral edema. He became hypertensive (190/115 mm Hg) and responded to hydralazine and hyperventilation. At 72 hours after ingestion, an EEG indicated brain death. Life support was discontinued.

Case 363. A 19-year-old man ingested five bags of cocaine and presented with tachydysrhythmias and shallow respirations. He was intubated and ventilated, and underwent lavage; charcoal and a cathartic were administered. His tachycardia responded to propranolol. Six hours after presentation, he was extubated. Twelve hours after presentation, he arrested and could not be resuscitated. Cocaine toxicity was confirmed by the medical examiner.

Case 386. A 25-year-old woman presented after injecting heroin, snorting cocaine, and ingesting diaz-

epam. She arrested and was resuscitated with naloxone and dopamine. Her blood pressure was 40 mm Hg, and her temperature was 28.9° C. The hypothermia was due to her boyfriend packing her in ice. She underwent intubation, ventilation, and lavage. Aspiration pneumonia was suspected, but by four hours after admission, she had fulminant pulmonary edema. The PO₂ on 100% oxygen was 50 mm Hg. Naloxone, dopamine, and dobutamine infusions were required. She arrested several times during the night. By the second day after ingestion, no brain stem functions were present. She died from hypoxic encephalopathy and ARDS.

Case 405. A 52-year-old man was exposed to 250 ml of povidone iodine, which was accidently dropped into his chest cavity during a thoracotomy. His condition deteriorated one hour after the incident. Metabolic acidosis and hypotension required dopamine and large volumes of fluid. Urine output remained low. Aggressive physical therapy and lavage of the povidone iodine from the tracheobronchial tree were employed. He continued to deteriorate, remained acidotic, and died.